Insight of immune checkpoint blockades in melanoma: mechanism and clinical translation Authors: Qingyan Zhang, Chunhui Yuan, Lin Zhu, Shaobing Zheng, Yantao Xu, Xuanlin Che, Shiyu Xiao, Juan Liu, Hong Liu, Hui Li, Xiang Chen Published: 2026 ABSTRACT Melanoma, a malignant tumor originating from melanocytes, accounts for only 4% of all skin cancers but is responsible for 75% of skin cancer-related deaths. In recent years, its incidence has steadily increased. Targeted therapies and immunotherapies have made significant strides, emerging as the most effective treatments for metastatic melanoma. Immune checkpoint blockades (ICBs) have become a central component of systemic therapy for advanced melanoma. However, their clinical use is limited by immune-related toxicities, primary and acquired resistance, and marked inter-patient heterogeneity in response. As a result, personalized treatment approaches are urgently needed. This paper provides a comprehensive review of recent advancements in melanoma immunotherapy, synthesizing findings from existing research and clinical trials. It highlights the progress made in understanding various immune checkpoints in melanoma and the outcomes of clinical trials involving different ICBs. The aim is to inform clinicians and patients about the latest developments in ICBs therapy while underscoring the critical role of personalized medicine in addressing the diverse needs of patients. Ultimately, the research seeks to catalyze further exploration and innovation in melanoma treatment.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12943-026-02694-7. Introduction Melanoma, a malignant tumor originating from melanocytes, poses a significant challenge in dermatological oncology. Data from the Centers for Disease Control and Prevention indicates that melanoma, despite being only 4% of skin cancer cases, leads to 75% of skin cancer deaths [1]. Although relatively rare, with an incidence of approximately 22.1 cases per 100,000 people in the United States, melanoma’s incidence has been steadily rising. From 2015 to 2019, the incidence increased by 2%−3% annually. In 2026, an estimated 112,000 new melanoma cases will be diagnosed, with 8,510 projected deaths [2], highlighting the urgent need for novel therapeutic approaches. Melanoma treatment has evolved considerably over the years. Surgical intervention remains the cornerstone for localized melanoma, involving the excision of the tumor and adjacent healthy tissue. In particular circumstances, surgery can be used to remove metastatic tumors, but this does not guarantee a cure, highlighting the need for additional therapeutic approaches [3]. Chemotherapy, traditionally the primary treatment for metastatic melanoma, has seen limited success. Dacarbazine, the first and only FDA-approved chemotherapy drug for melanoma since its introduction in 1975, provides a median survival of only 5–11 months, with only 27% surviving beyond one year [4]. No subsequent chemotherapeutic agents have surpassed its efficacy or reduced its toxicity. Recent advancements in melanoma treatment, however, have been rapid. The emergence of targeted therapies and immunotherapies has substantially improved outcomes for patients with metastatic melanoma, decreasing the reliance on chemotherapy. Targeted therapies aim to address the molecular defects present in melanoma. The most commonly used are B-Raf Proto-Oncogene, Serine/Threonine Kinase (BRAF) inhibitors, particularly for metastatic and unresectable BRAF-mutant melanoma. While these inhibitors exhibit remarkable efficacy in nearly half of patients, most develop secondary drug resistance within a short period, a mechanism that warrants further investigation [5, 6]. To date, immune checkpoint blockades (ICBs) have proven to be the most effective therapy for metastatic melanoma. Tumor cells often evade immune detection by manipulating immune checkpoints. A key mechanism involves programmed cell death protein 1 (PD-1), a protein found on the surfaces of T-cells that binds with its ligands, Programmed Death-Ligand 1/2 (PD-L1/2), on regular cells. This interaction suppresses the immune response and promotes self-tolerance, protecting healthy tissues from damage during immune responses. However, the overexpression of PD-L1/2 in cancers, including melanoma, frequently allows tumor cells to "switch off" immune responses and evade immune system destruction [7]. Another critical immune checkpoint, Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4), is primarily expressed on T lymphocytes and plays a pivotal role in regulating immune responses [8]. It functions as a co-inhibitory molecule, modulating T-cell activation and immune reactions [9]. In recent years, an increasing number of novel immune checkpoints has been identified, such as Lymphocyte-Activation Gene 3 (LAG-3), T-Cell Immunoglobulin and Mucin-Domain Containing-3 (TIM-3), CD73, CD155-T-Cell Immunoreceptor with Ig and ITIM Domains (TIGIT) axis, and CD276. These molecules modulate immune suppression and immune escape through orchestrating the crosstalk between tumor cells, antigen-presenting cells (APCs), and immune effector cells (Fig. 1). For melanoma, the most established immune checkpoint inhibitors in routine clinical use are pembrolizumab, nivolumab, nivolumab plus ipilimumab, and nivolumab plus relatlimab. By contrast, several other checkpoint-targeting antibodies, including PD-L1-directed agents and additional PD-1 antibodies used in other tumor types or jurisdictions, remain under investigation or have regulatory approval outside the melanoma setting [10]. However, the use of checkpoint inhibitors is associated with severe side effects, including inflammatory conditions related to the immune system that impact the skin, digestive tract, and endocrine glands. Furthermore, a considerable number of patients fail to respond to these therapies, and many who initially respond later develop secondary resistance to the drugs. Furthermore, the high cost of immune checkpoint inhibitor therapy remains a major barrier [11].Fig. 1Immune checkpoint interactions in tumor microenvironment. There are various immune checkpoint interactions between tumor cells, T-cells, and antigen-presenting cells (APCs) within the tumor microenvironment. The interactions are depicted as both inhibitory and stimulatory pathways, highlighting the complex regulatory network that can influence immune responses against tumors. Created in BioRender. zhang, Q. (2026) https://BioRender.com/fdxhz83 Immune checkpoint interactions in tumor microenvironment. There are various immune checkpoint interactions between tumor cells, T-cells, and antigen-presenting cells (APCs) within the tumor microenvironment. The interactions are depicted as both inhibitory and stimulatory pathways, highlighting the complex regulatory network that can influence immune responses against tumors. Created in BioRender. zhang, Q. (2026) https://BioRender.com/fdxhz83 Given the complexities of melanoma, no single treatment can provide a definitive solution. Consequently, the development of more effective and safer immune checkpoint inhibitors, alongside a personalized approach to treatment, is essential. This review aims to summarize recent advancements in both the foundational research and clinical trials related to key immune checkpoints in melanoma. The primary objective is to provide a comprehensive understanding of the current landscape, major challenges, and emerging directions of ICB-based therapies in melanoma. The review seeks to equip both clinicians and patients with the necessary knowledge to make informed decisions regarding optimal therapeutic options. General introduction of immune checkpoints Immune checkpoints are physiologic inhibitory pathways that restrain T-cell activation, maintain self-tolerance and limit collateral tissue damage; tumors hijack these pathways to evade eradication. The last decade has therefore witnessed explosive clinical translation of antibodies that block PD-1, PD-L1 and CTLA-4, while a growing portfolio of next-generation checkpoints—LAG-3, TIM-3, CD73, CD155-TIGIT, CD28 and B7-H3/CD276—are now entering trials. Here we provide a concise bench-to-bedside overview of these ten molecules, summarising their molecular logic, expression control and therapeutic status. PD-1 PD-1 is an inhibitory receptor of the CD28 superfamily expressed by activated T, B and NK cells [12]. Engagement of PD-1 by PD-L1 or PD-L2 delivers an ITIM/ITSM-based signal that recruits SHP-2, dampens TCR signaling and curtails cytokine output [13–17]. Transient PD-1 induction during acute infection is reversible and silenced by remethylation of distal enhancers (CR-B/CR-C) [18, 19]. Persistent antigen in cancer, however, triggers NF-κB, NFATc1, STAT3/4 and FOXO1-mediated demethylation, locking PD-1 into high expression that marks and sustains T-cell exhaustion [20–26]. Type-I IFN and IL-7 can transiently restrain PD-1 during viral hepatitis, whereas TGF-β1 and IFN-α further elevate it within the tumor micro-environment (TME) [27–29] (Fig. 2). FDA-approved PD-1 antibodies (nivolumab, pembrolizumab) produce durable responses in melanoma, NSCLC, MSI-high colorectal cancer and multiple other indications [30–32]; current efforts focus on combinations with chemotherapy, anti-VEGF, CTLA-4 or LAG-3 blockade to overcome primary or acquired resistance.Fig. 2Regulation of PD-1/PD-L1 Expression in T-Cells and Tumor Cells. It highlights the inflammatory factors and pertinent molecules that regulate the transcription, translation, and post-translational modifications of PD-1/PD-L1 in both T-cells and tumor cells. Created in BioRender. zhang, Q. (2026) https://BioRender.com/rdvr7sp Regulation of PD-1/PD-L1 Expression in T-Cells and Tumor Cells. It highlights the inflammatory factors and pertinent molecules that regulate the transcription, translation, and post-translational modifications of PD-1/PD-L1 in both T-cells and tumor cells. Created in BioRender. zhang, Q. (2026) https://BioRender.com/rdvr7sp PD-L1 PD-L1, the dominant PD-1 ligand, is constitutively low but rapidly up-regulated in malignant cells, dendritic cells and macrophages by oncogenic MYC, ALK, EGFR, PTEN-loss, HIF-1α and NF-κB signaling [33–39]. Inflammatory cytokines (IFN-γ, TNF-α, IL-6/17/27, TLR3, type-I IFN) activate JAK/STAT1 or MAPK cascades that enhance transcription, whereas hypoxia stabilizes HIF-1α-bound promoter elements [40–48]. Post-transcriptional control is provided by miR-200, miR-34a, miR-152 and miR-424 that target the 3′-UTR; loss of these miRNAs lifts translational repression [47, 49–52]. Epigenetically, PD-L1 promoter methylation silences expression, whereas HDAC or BET-mediated histone acetylation facilitates transcription [53–57]. Protein abundance is further calibrated by ubiquitin ligases (β-TrCP, CMTM6, TRIM21, KEAP1, SPOP) that tag PD-L1 for proteasomal destruction, while deubiquitinases USP22 and USP51 oppose this degradation [58–66]. Autophagy also participates: HIP1R or sunitinib reroute PD-L1 to lysosomes [67–70] (Fig. 2). PD-L1-directed antibodies (atezolizumab, durvalumab, avelumab) are approved for urothelial carcinoma, NSCLC and triple-negative breast cancer, with phase-III trials exploring combinations with CTLA-4, VEGF or TIGIT blockade [71–74]. To date, no FDA-approved PD-L1 monoclonal antibody has been approved for the treatment of melanoma. CTLA-4 CTLA-4 (CD152) competes with CD28 for B7-1/B7-2 binding, delivering a higher-affinity off-signal that aborts early T-cell activation [75, 76]. Transcription is initiated by NFAT/AP-1 during TCR engagement and amplified by FOXP3 in Tregs, whereas Runx and NF-κB can attenuate expression [77–80]. DNA demethylation and histone acetylation within the promoter, together with IL-2–STAT5 feedback, stabilize CTLA-4 mRNA, while miR-487a-3p has been implicated in diabetes-related down-modulation [81–83]. Intracellular trafficking is tightly choreographed by AP-1/AP-2 adaptors that cycle CTLA-4 between endosomes and the immunological synapse [84, 85]. Ipilimumab, the first checkpoint inhibitor to reach oncology clinics, improve overall survival in metastatic melanoma [86]; dual PD-1 + CTLA-4 blockade yields superior response rates but higher toxicity [87], and trials combining CTLA-4 antibodies with oncolytic viruses or radiotherapy are ongoing. LAG-3 LAG-3 (CD223) is a CD4-related trans-membrane protein that binds MHC-II with higher affinity than CD4, while additional ligands include FGL1 and heparin sulfate [88–90]. Its intracellular KIEELE motif is indispensable for inhibitory signaling, cell-cycle arrest and co-aggregation with PD-1 [91]. Expression is induced by IL-2, IL-7 and IL-12 on activated CD4 +/CD8 + T cells, is constitutive on Tregs and plasmacytoid DCs, and is proteolytically shed as soluble LAG-3 [92, 93]. Chronic antigen exposure retains LAG-3 on the surface of exhausted T cells, making it an attractive combinatorial target. Relatlimab (anti-LAG-3) plus nivolumab recently improved progression-free survival versus nivolumab alone in untreated melanoma, leading to FDA approval of the fixed-dose combination [94]. TIM-3 TIM-3 (HAVCR2) distinguishes exhausted CD8 + T cells through engagement of galectin-9, phosphatidylserine or ferritin, triggering phosphorylation-dependent inhibitory cascades that blunt proliferation and can induce death [95–97]. NFAT and the transcription factor T-bet drive TIM-3 transcription upon repeated TCR stimulation, whereas IL-10 and IL-27 promote epigenetic remodeling at the Havcr2 locus [98–100]. TIM-3 is additionally expressed on Tregs and MDSCs, augmenting their suppressor function and survival [101, 102]. Although no TIM-3-directed agent has yet entered routine melanoma practice, several antibodies are in early-phase clinical development. Several TIM-3 antibodies are currently in phase I/II trials as monotherapy or in triple combinations with PD-1 ± LAG-3 inhibitors. Available data suggest that TIM-3 remains biologically attractive as a resistance-associated checkpoint, but clinical evidence in melanoma is still preliminary and insufficient to define efficacy relative to established PD-1- or LAG-3-based regimens. CD73 CD73 (ecto-5′-nucleotidase) catalyses the final step of the adenosinergic pathway, converting extracellular AMP to immunosuppressive adenosine that dampens T-cell and NK-cell activity [103–105]. Hypoxia-inducible HIF-1α, TGF-β–SMAD, STAT3/4 and cAMP-response elements within the NT5E promoter cooperatively up-regulate CD73 in tumors, endothelial cells and MDSCs [106–111]. Conversely, oestrogen receptor signaling and promoter CpG methylation restrain expression; a truncated intracellular isoform can even trigger full-length CD73 degradation [112–114]. Pharmacological CD73 inhibition (oleclumab, quemliclustat) or genetic knock-down enhances anti-PD-1 efficacy in murine models [115], and early-phase studies are evaluating anti-CD73 antibodies combined with PD-1/PD-L1 blockade in solid tumors [116, 117]. CD155 The poliovirus receptor CD155 (PVR) and its cognate inhibitory receptor TIGIT constitute an emerging checkpoint axis. CD155 is over-expressed on many tumors following Ras–Raf–MEK–ERK activation and growth-factor signaling, and exists as trans-membrane (α, δ) or soluble (β, γ) isoforms; the α-isoform carries an ITIM that recruits SHP-2 to propagate inhibitory signals [118–125]. TIGIT competes with the co-stimulatory receptor CD226 for CD155 binding, thereby attenuating T-cell and NK-cell cytotoxicity; CD96 adds an additional layer of suppression, although its signaling logic remains incompletely defined [126–139]. Monalizumab (anti-NKG2A) plus durvalumab has validated co-blockade of paired inhibitory receptors [140]; similarly, anti-TIGIT antibodies tiragolumab combined with atezolizumab improve objective response and PFS in PD-L1-positive NSCLC, prompting phase III registration trials [141]. CD28 CD28 is the archetypal co-stimulatory receptor whose ligation by B7-1/B7-2 is obligatory for full T-cell activation, IL-2 production and metabolic reprogramming [142–146]. Signals downstream of CD28 also shape epigenetic fate decisions and can be subverted in cancer or exaggerated in autoimmunity [147–149]. Agonist CD28 antibodies (theralizumab) proved excessively toxic [150], whereas second-generation constructs that conditionally boost CD28 signaling only within the TME, or bispecific antibodies that tether CD28 to tumor antigens, are being re-explored to potentiate CAR-T and PD-1-directed therapies. CD276 Finally, B7-H3 (CD276) was initially described as a co-stimulator, but is now recognized as a bifunctional checkpoint whose engagement can both amplify and restrain T-cell responses depending on context [151–153]. Expression on APCs and tumors is driven by Sp1, AP-1, NF-κB and PI3K/AKT/mTOR signaling, and is further enhanced by BRD4, ILT-4 and ELK1 at the epigenetic level [154–162]. Post-transcriptional repression is mediated by miR-29 and miR-124, whereas HuR stabilizes B7-H3 mRNA; MDM2-directed ubiquitination can terminate protein expression [163–166]. Hypoxia, IFN-γ and TNF-α further elevate B7-H3, correlating with adverse prognosis across multiple cancers [167–169]. CD276 is likewise under active translational development, although no agents have yet been approved. In addition to monoclonal antibodies such as enoblituzumab undergoing phase I/II evaluation as monotherapy or in combination with PD-1 inhibitors [170], newer strategies including antibody–drug conjugates, bispecific T-cell engagers/DART constructs, and CAR-T products are entering phase I/II evaluation. Nevertheless, these agents remain early-stage, and no CD276-targeted therapy is currently approved for melanoma. Clinical picture of PD-1 inhibitor drugs Given the pivotal role of PD-1 as an immune checkpoint, substantial research efforts have focused on the development of PD-1 inhibitors and PD-1-based combinations. At present, pembrolizumab and nivolumab are FDA-approved PD-1 antibodies for melanoma, and nivolumab-based combinations with ipilimumab or relatlimab are also approved for unresectable or metastatic melanoma. Toripalimab is approved by the National Medical Products Administration (NMPA) of China for melanoma and several other solid tumor types, while sintilimab, camrelizumab, and tislelizumab are approved by NMPA for various advanced solid tumors (Table 1). Pembrolizumab received accelerated approval in 2014 based on the phase II KEYNOTE-002 trial in ipilimumab-refractory disease (NCT01704287) [171], followed by full approval for first-line treatment in 2015 based on the phase III KEYNOTE-006 trial (NCT01866319 [172], in which pembrolizumab improved ORR (33% versus 12% with ipilimumab), progression-free survival (HR 0.58, P < 0.001), and overall survival (median 32.7 versus 15.9 months; HR 0.71) with lower grade 3–5 treatment-related adverse events. Nivolumab was approved on the basis of CheckMate-066 (phase III versus dacarbazine, NCT01721772) [173] and CheckMate-067 (phase III combination with ipilimumab, NCT01844505) [174]. Five-year CheckMate-066 data show nivolumab yields 39% OS vs 17% dacarbazine, 28% vs 3% PFS and 42% vs 14% ORR; 88% of nivolumab complete responders remain alive and 83% of survivors need no subsequent therapy, confirming durable, treatment-free survival benefit with first-line nivolumab in BRAF-wild-type advanced melanoma (NCT01721772). Ten-year CheckMate-067 outcomes show median OS 71.9 mo with nivolumab–ipilimumab, 36.9 mo with nivolumab and 19.9 mo with ipilimumab; corresponding melanoma-specific survival remains NR (37% alive) versus 49.4 versus 21.9 mo. Among 3-year PFS survivors, 10-year MSS is 96%, 97% and 88%, confirming durable, treatment-free survival advantage of PD-1-based regimens over ipilimumab alone in advanced melanoma (NCT01844505). Toripalimab received conditional NMPA approval in December 2018 for previously treated unresectable or metastatic melanoma based on the phase II POLARIS-01 trial (NCT03013101), which reported an objective response rate of 17.3%, disease control rate of 57.5%, and median overall survival of 22.2 months in a predominantly acral and mucosal melanoma population [175]. This was converted to regular approval in January 2025. In April 2025, toripalimab gained NMPA approval for first-line treatment of advanced melanoma based on the phase III MELATORCH trial (NCT03430297), which demonstrated improved DOR to 13.8 months [176].Table 1Clinical trials of PD-1 inhibitorsDrugsNCT numberConditionsPhasesNumber of ParticipantsAEsEfficacyall grade TRAEs >/= G3 TRAEsORRDCRPFSOSPembrolizumab (anti PD-1) Compared With Ipilimumab (anti CTLA-4)NCT01866319ipilimumab-refractory Melanoma3834NAPembrolizumab 13.3%, ipilimumab 19.9%42% vs 17%NAthe median PFS was 5.5 months with pembrolizumab versus 2.8 months with ipilimumabthe median OS was 32.7 months with pembrolizumab versus 15.9 months with ipilimumabNivolumab (anti PD-1) Compared With Dacarbazine (chemotherapy drug)NCT01721772Melanoma3418, Nivolumab (n = 210) or Dacarbazine (n = 208)Nivolumab (60%),Dacarbazine (79.33%)Nivolumab (60.68%),Dacarbazine (58.05%)Nivolumab (42%),Dacarbazine (14%)NANivolumab (28%),the median PFS in the Nivolumab group (5.06 months[95% CI, 3.52–12.16])Nivolumab (39%),Dacarbazine(17%)Nivolumab (anti PD-1) or Nivolumab Plus Ipilimumab (anti CTLA-4) Versus Ipilimumab AloneNCT01844505Unresectable or Metastatic Melanoma3945, Nivolumab + Ipilimumab (n = 314) or Nivolumab (n = 316) or Ipilimumab (n = 315)Nivolumab + Ipilimumab (55.10%),Nivolumab (60.76%),Ipilimumab(77.14%)Nivolumab + Ipilimumab (79.55%),Nivolumab (59.74%),Ipilimumab(65.92%)Nivolumab + Ipilimumab (58.3%),Nivolumab (44.9%),Ipilimumab(19.0%)NANivolumab + Ipilimumab group (11.50 months [95% CI, 8.90–16.72]),Nivolumab group (6.87 months [95% CI, 4.34–9.46]), Ipilimumab group (2.89 months [95% CI, 2.79–3.42])Nivolumab + Ipilimumab group (71.9 months),Nivolumab group (36.9 months), Ipilimumab group (19.9 months)toripalimab (JS001,PD-1 inhibitor)NCT03013101advanced melanoma212890.6%25%17.3%57.5%Median PFS was 3.6 months (95% confidence interval (CI) 2.7–5.3)Median OS was 22.2 months (95% CI, 15.3-NE)toripalimab (JS001,PD-1 inhibitor)NCT02836795Melanoma;Urothelial Carcinoma;Renal Cell Carcinoma136hyper- or hypo-thyroidism (42%), rash (39%), fever (28%), leukopenia (22%), elevation of liver enzymes (19%), anorexia (17%), and fatigue (14%)proteinuria (n = 1), and lipase increase (n = 2)7/32(22%)17/32(53%)NANAtoripalimab (JS001,PD-1 inhibitor) vs dacarbazineNCT03430297advanced melanoma3256 (127 in toripalimab)70%15%14% vs 11%40% vs 45%The median DOR was 13.8 months (95% CI, 5.9 to NE) vs 6.9 months (95% CI, 3.8 to NE)NAtoripalimab(JS001,PD-1 inhibitor) versus high-dose IFN-a2bNCT03178123resected mucosal melanoma2145 were randomized into HDI group (n = 72) and toripalimab group (n = 73)NA83.3% of pts in HDI group (most decrease of leukocytes or neutrophils) and 15.1% of pts in toripalimab groupNANANANAretifanlimab (INCMGA00012,PD-1 inhibitor))NCT03679767Solid Tumors2121 (35 melanoma)asthenia (17.4%), arthralgia (14.9%), decreased appetite (14.0%), pruritus (12.4%), rash (10.7%), and urinary tract infection (10.7%)NA13/35(37.1%)19/35(54.3%)NANAprolgolimab(PD-1 inhibitor)NCT05783882Unresectable or Metastatic Melanoma3114NANANANANANATislelizumab(PD-1 inhibitor)CTR20160872advanced solid tumors1/230062%, anemia (n = 70; 23%) and increased aspartate aminotransferase (n = 67; 22%)NA45/251(18%)NANANANeoadjuvant Pembrolizumab(PD-1 inhibitor)NCT02306850Unresectable Stage III and Unresectable Stage IV Melanoma210100%30%Resectability Rate 80%NANANAnivolumab(PD-1 inhibitor) vs either Dacarbazine or CarboplatinNCT01721746Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy3405, 272 in A(nivo), 133 in B(Dacarbazine or Carboplatin)95.15%in A, 93.14%in B71.27%in A, 36.27%in B74/272(27.2%) in A, 13/133(9.8%)in BNAMedian PFS was 3.12 months (95%CI: 2.33–3.52)in A, 3.65 months(95%CI: 2.30–5.29)in BMedian OS was 15.74 months (95%CI: 12.88–19.88)in A, 14.39 months(95%CI: 11.66–18.17)in B Table 1Clinical trials of PD-1 inhibitorsDrugsNCT numberConditionsPhasesNumber of ParticipantsAEsEfficacyall grade TRAEs >/= G3 TRAEsORRDCRPFSOSPembrolizumab (anti PD-1) Compared With Ipilimumab (anti CTLA-4)NCT01866319ipilimumab-refractory Melanoma3834NAPembrolizumab 13.3%, ipilimumab 19.9%42% vs 17%NAthe median PFS was 5.5 months with pembrolizumab versus 2.8 months with ipilimumabthe median OS was 32.7 months with pembrolizumab versus 15.9 months with ipilimumabNivolumab (anti PD-1) Compared With Dacarbazine (chemotherapy drug)NCT01721772Melanoma3418, Nivolumab (n = 210) or Dacarbazine (n = 208)Nivolumab (60%),Dacarbazine (79.33%)Nivolumab (60.68%),Dacarbazine (58.05%)Nivolumab (42%),Dacarbazine (14%)NANivolumab (28%),the median PFS in the Nivolumab group (5.06 months[95% CI, 3.52–12.16])Nivolumab (39%),Dacarbazine(17%)Nivolumab (anti PD-1) or Nivolumab Plus Ipilimumab (anti CTLA-4) Versus Ipilimumab AloneNCT01844505Unresectable or Metastatic Melanoma3945, Nivolumab + Ipilimumab (n = 314) or Nivolumab (n = 316) or Ipilimumab (n = 315)Nivolumab + Ipilimumab (55.10%),Nivolumab (60.76%),Ipilimumab(77.14%)Nivolumab + Ipilimumab (79.55%),Nivolumab (59.74%),Ipilimumab(65.92%)Nivolumab + Ipilimumab (58.3%),Nivolumab (44.9%),Ipilimumab(19.0%)NANivolumab + Ipilimumab group (11.50 months [95% CI, 8.90–16.72]),Nivolumab group (6.87 months [95% CI, 4.34–9.46]), Ipilimumab group (2.89 months [95% CI, 2.79–3.42])Nivolumab + Ipilimumab group (71.9 months),Nivolumab group (36.9 months), Ipilimumab group (19.9 months)toripalimab (JS001,PD-1 inhibitor)NCT03013101advanced melanoma212890.6%25%17.3%57.5%Median PFS was 3.6 months (95% confidence interval (CI) 2.7–5.3)Median OS was 22.2 months (95% CI, 15.3-NE)toripalimab (JS001,PD-1 inhibitor)NCT02836795Melanoma;Urothelial Carcinoma;Renal Cell Carcinoma136hyper- or hypo-thyroidism (42%), rash (39%), fever (28%), leukopenia (22%), elevation of liver enzymes (19%), anorexia (17%), and fatigue (14%)proteinuria (n = 1), and lipase increase (n = 2)7/32(22%)17/32(53%)NANAtoripalimab (JS001,PD-1 inhibitor) vs dacarbazineNCT03430297advanced melanoma3256 (127 in toripalimab)70%15%14% vs 11%40% vs 45%The median DOR was 13.8 months (95% CI, 5.9 to NE) vs 6.9 months (95% CI, 3.8 to NE)NAtoripalimab(JS001,PD-1 inhibitor) versus high-dose IFN-a2bNCT03178123resected mucosal melanoma2145 were randomized into HDI group (n = 72) and toripalimab group (n = 73)NA83.3% of pts in HDI group (most decrease of leukocytes or neutrophils) and 15.1% of pts in toripalimab groupNANANANAretifanlimab (INCMGA00012,PD-1 inhibitor))NCT03679767Solid Tumors2121 (35 melanoma)asthenia (17.4%), arthralgia (14.9%), decreased appetite (14.0%), pruritus (12.4%), rash (10.7%), and urinary tract infection (10.7%)NA13/35(37.1%)19/35(54.3%)NANAprolgolimab(PD-1 inhibitor)NCT05783882Unresectable or Metastatic Melanoma3114NANANANANANATislelizumab(PD-1 inhibitor)CTR20160872advanced solid tumors1/230062%, anemia (n = 70; 23%) and increased aspartate aminotransferase (n = 67; 22%)NA45/251(18%)NANANANeoadjuvant Pembrolizumab(PD-1 inhibitor)NCT02306850Unresectable Stage III and Unresectable Stage IV Melanoma210100%30%Resectability Rate 80%NANANAnivolumab(PD-1 inhibitor) vs either Dacarbazine or CarboplatinNCT01721746Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy3405, 272 in A(nivo), 133 in B(Dacarbazine or Carboplatin)95.15%in A, 93.14%in B71.27%in A, 36.27%in B74/272(27.2%) in A, 13/133(9.8%)in BNAMedian PFS was 3.12 months (95%CI: 2.33–3.52)in A, 3.65 months(95%CI: 2.30–5.29)in BMedian OS was 15.74 months (95%CI: 12.88–19.88)in A, 14.39 months(95%CI: 11.66–18.17)in B Clinical trials of PD-1 inhibitors Nivolumab (60%), Dacarbazine (79.33%) Nivolumab (60.68%), Dacarbazine (58.05%) Nivolumab (42%), Dacarbazine (14%) Nivolumab (28%), the median PFS in the Nivolumab group (5.06 months[95% CI, 3.52–12.16]) Nivolumab (39%), Dacarbazine (17%) Nivolumab + Ipilimumab (55.10%), Nivolumab (60.76%), Ipilimumab (77.14%) Nivolumab + Ipilimumab (79.55%), Nivolumab (59.74%), Ipilimumab (65.92%) Nivolumab + Ipilimumab (58.3%), Nivolumab (44.9%), Ipilimumab (19.0%) Nivolumab + Ipilimumab group (11.50 months [95% CI, 8.90–16.72]), Nivolumab group (6.87 months [95% CI, 4.34–9.46]), Ipilimumab group (2.89 months [95% CI, 2.79–3.42]) Nivolumab + Ipilimumab group (71.9 months), Nivolumab group (36.9 months), Ipilimumab group (19.9 months) Moreover, there is growing interest in the potential synergy between PD-L1 inhibitors and different therapeutic approaches, like targeted treatments and inhibitors of angiogenesis, as outlined in Table 2.Table 2Clinical trials of PD-1 inhibitors combination therapyDrugsNCT numberConditionsPhasesNumber of ParticipantsAEsEfficacyall grade TRAEs >/= G3 TRAEsORRDCRPFSOSToripalimab(JS001,T,PD-1 inhibitor) plus axitinib(A,a VEGF receptor inhibitor) versus toripalimab or axitinib aloneNCT03941795treatment-naive unresectable or metastatic mucosal melanoma251(18 to T + A, 20 to T, and 13 to A)80.40%33.3%, 30.0%, 30.8% of patients in T + A, T, A groups35.3%(T + A);17.6%(T);8.3%(A)NAThe median PFS 5.83 vs 2.80 vs 1.40 months;(HR = 0.538; 95% CI, 0.237 to 1.221; HR = 0.444; 95% CI, 0.182 to 1.081; P = 0.170)NAcamrelizumab (CAM,PD-1 inhibitor) combined with apatinib (APA, a VEGFR-2 tyrosine kinase inhibitor) and temozolomide (TMZ)NCT04397770advanced acral melanoma25094%γ-glutamyl transferase elevation (24.0%), direct bilirubin elevation (22.0%), aspartase transaminase elevation (20.0%), alanine transaminase elevation (16.0%), and hypertriglyceridemia (14.0%)31/48(64.6%)46/48(95.8%)NANAneoadjuvant lenvatinib(VEGFR inhibitor) and pembrolizumab(PD-1 inhibitor)NCT04622566resectable mucosal melanoma219proteinuria (6, 32%), hypothyroidism (6, 32%), dysphonia (5, 26%)5%6/15(40%)NANANAneoadjuvant lenvatinib(VEGFR inhibitor) and pembrolizumab(PD-1 inhibitor)NCT02501096advanced melanoma1b/221fatigue (52%), decreased appetite (48%), diarrhea (48%), hypertension (48%), dysphonia (43%), and nausea (43%)67%10/21(47.6%)17/21(81%)Median PFS 7.6 months (95% CI:2.6–15.8)NAneoadjuvant lenvatinib(VEGFR inhibitor) and pembrolizumab(PD-1 inhibitor)NCT03776136advanced melanoma210396.10%45.60%22/103(21.4%)68/103(66%)Median PFS 4.2 months (95% CI:3.8–7.1)Median OS 14.0 months (95% CI 10.8-NR)neoadjuvant lenvatinib(VEGFR inhibitor) and pembrolizumab(PD-1 inhibitor)NCT04889118unresectable or metastatic melanoma313196.9% in the len + pembro arm vs 97.0% in the pbo + pembro arm62.5% in the len + pembro arm vs 16.4% in the pbo + pembro armORR was 26.6% (95% CI, 16.3–39.1; 4 CR, 13 PR) for len + pembro vs 16.4% (95% CI, 8.5–27.5; 4 CR, 7 PR) for pbo + pembromedian DOR was 13.7 mo (range, 3.8–21.4) vs NR (range, 4.2–21.4 +)median PFS was 6.1 mo (95% CI, 4.1–8.1) for len + pembro vs 2.0 mo (95% CI, 2.0–2.1) for pbo + pembro (HR, 0.55; 95% CI, 0.37–0.81)Median OS was 19.9 mo (95% CI, 11.9–26.8) for len + pembro vs 17.0 mo (95% CI, 12.7–25.7) for pbo + pembro (HR, 0.93; 95% CI, 0.58–1.48)vorolanib (CM082,multi-target tyrosine kinase inhibitor including VEGF, PDGF, c-kit, and Flt-3) in combination with toripalimab (JS001,PD-1 inhibitor)NCT03602547advanced mucosal melanoma240(19 pts in 150 mg group; 21 pts in 200 mg group),38 pts were evaluable for tumor response (150 mg n = 18, 200 mg n = 20)NANA4/18(22.2%);3/20(15%)10/18(55.6%);13/20(65%)The median PFS was 5.7 (95% CI 2.0, NE) months and 5.6 (1.9, 7.7) months in the two groups, respectivelyNAcamrelizumab(PD-1 inhibitor) combined with famitinib(multiple-target tyrosine kinase inhibitor)NCT05051865advanced acral and mucosal melanoma21888.90%11.10%3/17(17.6%)11/17(64.7%)The median PFS was 6.0 monthsNANivolumab(PD-1 inhibitor)/Ipilimumab(CTLA-4 inhibitor)plus cabozantinib(c-MET/VEGFR2 inhibitor)NCT04091750unresectable advanced melanoma21493%64%6/13(46%)7/13(54%)median PFS 10.3 monthsNApucotenlimab(PD-1 inhibitor) plus intrahepatic injection of oncolytic virus (OH2) combined with radiotherapyNCT05068453liver metastasis in stage IV melanoma110NA10%2/5(40.0%)4/5(80%)NANAOrienX010 (a HSV-1-derived oncolytic virotherapy) in combination with toripalimab (JS001,T,PD-1 inhibitor)NCT04206358stage Ⅳ melanoma with liver metastases1b23NANA3/20(15%)10/20(50%)The median PFS was 7.0 months (95%CI: 4.3–9.7 months)the median OS was 18.6 months (95%CI: 13.4–23.7 months)pembrolizumab(PD-1 inhibitor) in combination with talimogene laherparepvec(oncolytic viral)NCT02263508melanoma22133%NA12/21(57%)NANANAVoyager V1 (VV1) oncolytic virus in combination with cemiplimab (PD-1 inhibitor) and ipilimumab(CTLA-4 inhibitor)NCT04291105melanoma and non–small cell lung cancer287NANANANANANAintratumoral SD-101(TLR9 stimulator) combination with pembrolizumabNCT02521870Advanced Melanoma1b9100%14%78%NA12-month PFS rate was 88%OS rate was 89%personalized neoantigen vaccine (EVX-01)combined with pembrolizumab (PD-1 inhibitor) or nivolumab(PD-1 inhibitor)NCT03715985Stage-IV metastatic melanoma1/212fatigue and injection site reactions08/12(67%)NANANAGEN-009(a personalized neoantigen vaccine)combined with PD-1 inhibitorNCT03633110advanced solid tumors1/215 in A(GEN-009 in combination with a PD-1 inhibitor); 1 in B(GEN-009 monotherapy)vaccine injection site reactions and mild myalgias or fatigueFour of 7 CPI refractory patients have experienced unexpected prolonged stable disease after vaccination of up to 8 months after vaccination3/15(20%) in A,0 in B11/15(73%) in A,0 in BNANAVigil™(autologous tumor cell vaccine) + Pembrolizumab(PD-1 inhibitor)NCT02574533Advanced Melanoma12NANANANANANAN803 (IL-15 superagonist) combined with PD-1 inhibitorNCT03228667solid tumors(data published all in NSLSC)2135injection site reaction (68%), chills (32%) fatigue (26%), pyrexia (26%), flu-like illness (14%), nausea (12%) and no other individual AE > 10%12%11/135(8%)79/135(59%)Median PFS 3.9 months (95% CI: 2.6,5.0)Median OS 13.8 months (95% CI: 11.8, 16.3)Combining Nivolumab(PD-1 inhibitor) and Ipilimumab(CTLA-4 inhibitor) with Infliximab(TNF-αinhibitor) or Certolizumab(TNF-αinhibitor)NCT03293784advanced melanoma1b6 in A(nivolumab + ipilimumab + infliximab),8 in B(nivolumab + ipilimumab + certolizumab)87.5% in A,100% in B75% in A,50% in B3/6(50%) in A,7/7(100%) in B3/6(50%) in A,7/7(100%) in BNANASarilumab(Interleukin-6 Receptor Inhibitor) in Combination With Ipilimumab(CTLA-4 inhibitor), Nivolumab(PD-1 inhibitor) and Relatlimab(LAG-3 inhibitor)NCT05428007Unresectable Stage III or Stage IV Melanoma23393.9% (n = 31)27% (n = 9)63.6% (95% CI: 45.1%, 79.6%)NANANAL-TIL(liquid tumor infiltrating lymphocytes) Plus Tislelizumab(PD-1 inhibitor)NCT04924413Advanced Malignant Melanoma230NANANANANANAnivolumab with concurrent radiotherapyjRCTs 1,051,200,028metastatic mucosal melanoma218NA35.2%41.2%64.7%4.9 months (95% (CI) 2.2–15.1 months)20.1 months (95% CI 7.5–31.5 months)PD-1 Inhibitors With or Without RadiationNCT05498805Advanced Melanoma292NANANANANANAMRx0518 (a strain of Enterococcus gallinarum) and Pembrolizumab (PD-1 inhibitor)NCT03637803Solid Tumors1/263NANANANANANAFecal Microbiota Transplant with Pembrolizumab(PD-1 inhibitor)NCT03341143Melanoma215100%18.2%20%40%3.0 months7.0 monthsBRAF/MEK inhibition vs combination nivolumab/ipilimumabNCT02224781treatment-naive BRAFV600-mutant metastatic melanoma3265NA59.5% in arm A, 53.1% in arm B, 53.8% in arm C, and 50.0% in arm Darm A: 46.0%; arm B: 43.0%; arm C: 47.8%; and arm D: 29.6%NANAThe 2-year OS for those starting on arm A was 71.8% (95% CI, 62.5 to 79.1) and arm B 51.5% (95% CI, 41.7 to 60.4; log-rank P =.010)entinostat (ENT, HDAC inhibitor) in combination with pembrolizumab(PD-1 inhibitor)NCT02437136melanoma253100.0%45.28%18.9(9.4 to 32.0)NANA12.52(8.51 to 28.25)etrumadenant (AB928,A2R inhibitor) in combination with zimberelimab (AB122,an anti-PD-1 antibody)NCT03629756Advanced Malignancies148NANANANANANARigosertib(PLK1 inhibitor) Plus Pembrolizumab(PD-1 inhibitor)NCT05764395Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors229NANANANANANACB-839(GLS1 inhibitor) in Combination With Nivolumab(PD-1 inhibitor)NCT02771626Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC)1/2118(37 melanoma)99.2%53.4%5.4%51.5%2.07 (1.87–3.75)NAL-NMMA(nitric oxide synthase inhibitor) and Pembrolizumab(PD-1 inhibitor)NCT03236935advanced solid tumors112NANANANANANAbelapectin(galectin-3 inhibitor) plus Pembrolizumab(PD-1 inhibitor)NCT02575404metastatic melanoma (MM) and head and neck squamous cell carcinoma (HNSCC)114 with melanomaNANA7/14(50%) of melanomaNANANALifileucel and PD-1 antibodyNCT02360579advanced melanoma2153NANA31.4%NANA13.9 months (95% CI: 10.6–17.8) Table 2Clinical trials of PD-1 inhibitors combination therapyDrugsNCT numberConditionsPhasesNumber of ParticipantsAEsEfficacyall grade TRAEs >/= G3 TRAEsORRDCRPFSOSToripalimab(JS001,T,PD-1 inhibitor) plus axitinib(A,a VEGF receptor inhibitor) versus toripalimab or axitinib aloneNCT03941795treatment-naive unresectable or metastatic mucosal melanoma251(18 to T + A, 20 to T, and 13 to A)80.40%33.3%, 30.0%, 30.8% of patients in T + A, T, A groups35.3%(T + A);17.6%(T);8.3%(A)NAThe median PFS 5.83 vs 2.80 vs 1.40 months;(HR = 0.538; 95% CI, 0.237 to 1.221; HR = 0.444; 95% CI, 0.182 to 1.081; P = 0.170)NAcamrelizumab (CAM,PD-1 inhibitor) combined with apatinib (APA, a VEGFR-2 tyrosine kinase inhibitor) and temozolomide (TMZ)NCT04397770advanced acral melanoma25094%γ-glutamyl transferase elevation (24.0%), direct bilirubin elevation (22.0%), aspartase transaminase elevation (20.0%), alanine transaminase elevation (16.0%), and hypertriglyceridemia (14.0%)31/48(64.6%)46/48(95.8%)NANAneoadjuvant lenvatinib(VEGFR inhibitor) and pembrolizumab(PD-1 inhibitor)NCT04622566resectable mucosal melanoma219proteinuria (6, 32%), hypothyroidism (6, 32%), dysphonia (5, 26%)5%6/15(40%)NANANAneoadjuvant lenvatinib(VEGFR inhibitor) and pembrolizumab(PD-1 inhibitor)NCT02501096advanced melanoma1b/221fatigue (52%), decreased appetite (48%), diarrhea (48%), hypertension (48%), dysphonia (43%), and nausea (43%)67%10/21(47.6%)17/21(81%)Median PFS 7.6 months (95% CI:2.6–15.8)NAneoadjuvant lenvatinib(VEGFR inhibitor) and pembrolizumab(PD-1 inhibitor)NCT03776136advanced melanoma210396.10%45.60%22/103(21.4%)68/103(66%)Median PFS 4.2 months (95% CI:3.8–7.1)Median OS 14.0 months (95% CI 10.8-NR)neoadjuvant lenvatinib(VEGFR inhibitor) and pembrolizumab(PD-1 inhibitor)NCT04889118unresectable or metastatic melanoma313196.9% in the len + pembro arm vs 97.0% in the pbo + pembro arm62.5% in the len + pembro arm vs 16.4% in the pbo + pembro armORR was 26.6% (95% CI, 16.3–39.1; 4 CR, 13 PR) for len + pembro vs 16.4% (95% CI, 8.5–27.5; 4 CR, 7 PR) for pbo + pembromedian DOR was 13.7 mo (range, 3.8–21.4) vs NR (range, 4.2–21.4 +)median PFS was 6.1 mo (95% CI, 4.1–8.1) for len + pembro vs 2.0 mo (95% CI, 2.0–2.1) for pbo + pembro (HR, 0.55; 95% CI, 0.37–0.81)Median OS was 19.9 mo (95% CI, 11.9–26.8) for len + pembro vs 17.0 mo (95% CI, 12.7–25.7) for pbo + pembro (HR, 0.93; 95% CI, 0.58–1.48)vorolanib (CM082,multi-target tyrosine kinase inhibitor including VEGF, PDGF, c-kit, and Flt-3) in combination with toripalimab (JS001,PD-1 inhibitor)NCT03602547advanced mucosal melanoma240(19 pts in 150 mg group; 21 pts in 200 mg group),38 pts were evaluable for tumor response (150 mg n = 18, 200 mg n = 20)NANA4/18(22.2%);3/20(15%)10/18(55.6%);13/20(65%)The median PFS was 5.7 (95% CI 2.0, NE) months and 5.6 (1.9, 7.7) months in the two groups, respectivelyNAcamrelizumab(PD-1 inhibitor) combined with famitinib(multiple-target tyrosine kinase inhibitor)NCT05051865advanced acral and mucosal melanoma21888.90%11.10%3/17(17.6%)11/17(64.7%)The median PFS was 6.0 monthsNANivolumab(PD-1 inhibitor)/Ipilimumab(CTLA-4 inhibitor)plus cabozantinib(c-MET/VEGFR2 inhibitor)NCT04091750unresectable advanced melanoma21493%64%6/13(46%)7/13(54%)median PFS 10.3 monthsNApucotenlimab(PD-1 inhibitor) plus intrahepatic injection of oncolytic virus (OH2) combined with radiotherapyNCT05068453liver metastasis in stage IV melanoma110NA10%2/5(40.0%)4/5(80%)NANAOrienX010 (a HSV-1-derived oncolytic virotherapy) in combination with toripalimab (JS001,T,PD-1 inhibitor)NCT04206358stage Ⅳ melanoma with liver metastases1b23NANA3/20(15%)10/20(50%)The median PFS was 7.0 months (95%CI: 4.3–9.7 months)the median OS was 18.6 months (95%CI: 13.4–23.7 months)pembrolizumab(PD-1 inhibitor) in combination with talimogene laherparepvec(oncolytic viral)NCT02263508melanoma22133%NA12/21(57%)NANANAVoyager V1 (VV1) oncolytic virus in combination with cemiplimab (PD-1 inhibitor) and ipilimumab(CTLA-4 inhibitor)NCT04291105melanoma and non–small cell lung cancer287NANANANANANAintratumoral SD-101(TLR9 stimulator) combination with pembrolizumabNCT02521870Advanced Melanoma1b9100%14%78%NA12-month PFS rate was 88%OS rate was 89%personalized neoantigen vaccine (EVX-01)combined with pembrolizumab (PD-1 inhibitor) or nivolumab(PD-1 inhibitor)NCT03715985Stage-IV metastatic melanoma1/212fatigue and injection site reactions08/12(67%)NANANAGEN-009(a personalized neoantigen vaccine)combined with PD-1 inhibitorNCT03633110advanced solid tumors1/215 in A(GEN-009 in combination with a PD-1 inhibitor); 1 in B(GEN-009 monotherapy)vaccine injection site reactions and mild myalgias or fatigueFour of 7 CPI refractory patients have experienced unexpected prolonged stable disease after vaccination of up to 8 months after vaccination3/15(20%) in A,0 in B11/15(73%) in A,0 in BNANAVigil™(autologous tumor cell vaccine) + Pembrolizumab(PD-1 inhibitor)NCT02574533Advanced Melanoma12NANANANANANAN803 (IL-15 superagonist) combined with PD-1 inhibitorNCT03228667solid tumors(data published all in NSLSC)2135injection site reaction (68%), chills (32%) fatigue (26%), pyrexia (26%), flu-like illness (14%), nausea (12%) and no other individual AE > 10%12%11/135(8%)79/135(59%)Median PFS 3.9 months (95% CI: 2.6,5.0)Median OS 13.8 months (95% CI: 11.8, 16.3)Combining Nivolumab(PD-1 inhibitor) and Ipilimumab(CTLA-4 inhibitor) with Infliximab(TNF-αinhibitor) or Certolizumab(TNF-αinhibitor)NCT03293784advanced melanoma1b6 in A(nivolumab + ipilimumab + infliximab),8 in B(nivolumab + ipilimumab + certolizumab)87.5% in A,100% in B75% in A,50% in B3/6(50%) in A,7/7(100%) in B3/6(50%) in A,7/7(100%) in BNANASarilumab(Interleukin-6 Receptor Inhibitor) in Combination With Ipilimumab(CTLA-4 inhibitor), Nivolumab(PD-1 inhibitor) and Relatlimab(LAG-3 inhibitor)NCT05428007Unresectable Stage III or Stage IV Melanoma23393.9% (n = 31)27% (n = 9)63.6% (95% CI: 45.1%, 79.6%)NANANAL-TIL(liquid tumor infiltrating lymphocytes) Plus Tislelizumab(PD-1 inhibitor)NCT04924413Advanced Malignant Melanoma230NANANANANANAnivolumab with concurrent radiotherapyjRCTs 1,051,200,028metastatic mucosal melanoma218NA35.2%41.2%64.7%4.9 months (95% (CI) 2.2–15.1 months)20.1 months (95% CI 7.5–31.5 months)PD-1 Inhibitors With or Without RadiationNCT05498805Advanced Melanoma292NANANANANANAMRx0518 (a strain of Enterococcus gallinarum) and Pembrolizumab (PD-1 inhibitor)NCT03637803Solid Tumors1/263NANANANANANAFecal Microbiota Transplant with Pembrolizumab(PD-1 inhibitor)NCT03341143Melanoma215100%18.2%20%40%3.0 months7.0 monthsBRAF/MEK inhibition vs combination nivolumab/ipilimumabNCT02224781treatment-naive BRAFV600-mutant metastatic melanoma3265NA59.5% in arm A, 53.1% in arm B, 53.8% in arm C, and 50.0% in arm Darm A: 46.0%; arm B: 43.0%; arm C: 47.8%; and arm D: 29.6%NANAThe 2-year OS for those starting on arm A was 71.8% (95% CI, 62.5 to 79.1) and arm B 51.5% (95% CI, 41.7 to 60.4; log-rank P =.010)entinostat (ENT, HDAC inhibitor) in combination with pembrolizumab(PD-1 inhibitor)NCT02437136melanoma253100.0%45.28%18.9(9.4 to 32.0)NANA12.52(8.51 to 28.25)etrumadenant (AB928,A2R inhibitor) in combination with zimberelimab (AB122,an anti-PD-1 antibody)NCT03629756Advanced Malignancies148NANANANANANARigosertib(PLK1 inhibitor) Plus Pembrolizumab(PD-1 inhibitor)NCT05764395Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors229NANANANANANACB-839(GLS1 inhibitor) in Combination With Nivolumab(PD-1 inhibitor)NCT02771626Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC)1/2118(37 melanoma)99.2%53.4%5.4%51.5%2.07 (1.87–3.75)NAL-NMMA(nitric oxide synthase inhibitor) and Pembrolizumab(PD-1 inhibitor)NCT03236935advanced solid tumors112NANANANANANAbelapectin(galectin-3 inhibitor) plus Pembrolizumab(PD-1 inhibitor)NCT02575404metastatic melanoma (MM) and head and neck squamous cell carcinoma (HNSCC)114 with melanomaNANA7/14(50%) of melanomaNANANALifileucel and PD-1 antibodyNCT02360579advanced melanoma2153NANA31.4%NANA13.9 months (95% CI: 10.6–17.8) Clinical trials of PD-1 inhibitors combination therapy solid tumors (data published all in NSLSC) 18.9 (9.4 to 32.0) 12.52 (8.51 to 28.25) Angiogenesis inhibitor combined with PD-1 antibody One notable combination study explored the pairing of toripalimab (a PD-1 inhibitor) with axitinib (a VEGF receptor inhibitor) in a Phase II clinical trial (NCT03941795). The trial enrolled 51 patients, who were randomized into three groups: 18 to toripalimab plus axitinib (T + A), 20 to toripalimab (T), and 13 to axitinib (A). The results indicated that 80.4% of patients experienced treatment-related adverse events (TRAEs), with 33.3% in the T + A group, 30.0% in the T group, and 30.8% in the A group reporting TRAEs of grade 3 or higher. The objective response rate (ORR) was 35.3% for the T + A group, 17.6% for the T group, and 8.3% for the A group. The median progression-free survival (PFS) was 5.83 months for the T + A group, compared to 2.80 months for the T group and 1.40 months for the A group. However, while the combination therapy demonstrated a better ORR and PFS, the differences were not statistically significant (HR = 0.538, 95% CI: 0.237 to 1.221; P = 0.170) [177]. Another trial investigated the combination of camrelizumab (a PD-1 inhibitor) with apatinib (a VEGFR-2 inhibitor) and temozolomide (NCT04397770). Among the patients, one achieved a complete response (CR), six achieved a partial response (PR), and 15 experienced stable disease (SD), ORR of 2.5% and a disease control rate (DCR) of 95.8% [178]. Lenvatinib, an oral multi-targeted tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors (VEGFR1-3), fibroblast growth factor receptors (FGFR1-4), platelet-derived growth factor receptor (PDGFR), Kinase Insert Domain Receptor (KDR), and rearranged during transfection (RET), has also been researched in conjunction with pembrolizumab (a PD-1 antibody) in multiple clinical trials. In NCT04622566, 15 patients underwent surgery, with 2 achieving a pathologic complete response (pCR), 1 showing a major pathologic response (MPR), and 3 showing a partial pathologic response (pPR), resulting in a pathologic response rate of 40% (6/15, 95% CI 16–67%). Four patients opted not to proceed with the planned surgery due to personal preference. The median event-free survival (EFS) has not yet been reached [179]. In NCT02501096, the ORR was 47.6%, and the DCR was 81%, with a median PFS of 7.6 months (95% CI: 2.6–15.8) [180]. In NCT03776136 (LEAP-004), the ORR was 21.4%, the DCR was 66%, the median PFS was 4.2 months (95% CI: 3.8–7.1), and the median overall survival (OS) was 14.0 months (95% CI: 10.8-NR) [181]. LEAP-003 global trial (NCT03820986) evaluation did not demonstrate an overall survival benefit over pembrolizumab alone in the first-line treatment of advanced melanoma. Findings from the China extension study (NCT04889118) revealed distinct efficacy patterns in Chinese patients. In this subgroup analysis, lenvatinib combined with pembrolizumab significantly improved progression-free survival compared with pembrolizumab alone (median PFS: 6.1 vs. 2.0 months; HR 0.55, 95% CI 0.37–0.81). Notably, patients with mucosal melanoma—a subtype predominant in the Chinese population—appeared to derive greater benefit from the combination, with a median PFS of 8.1 vs. 2.0 months (HR 0.44, 95% CI 0.20–0.97) and an objective response rate of 50.0% versus 7.1% in the placebo plus pembrolizumab arm. However, this enhanced efficacy was accompanied by a considerable increase in toxicity, with grade 3–5 treatment-related adverse events occurring in 62.5% of patients receiving the combination versus 16.4% in the monotherapy group [182]. These findings suggest that lenvatinib plus pembrolizumab may have differential activity across melanoma subtypes, particularly in mucosal melanoma, but the regimen remains investigational in melanoma overall. In addition, other angiogenesis inhibitors such as vorolanib (a multi-target tyrosine kinase inhibitor) with toripalimab, famitinib (another multi-target tyrosine kinase inhibitor) with camrelizumab, and cabozantinib (a c-MET/VEGFR2 inhibitor) with nivolumab or ipilimumab have been assessed in various clinical experiments (NCT03602547, NCT05051865, NCT04091750) [183–185], but available evidence remains limited and these approaches should presently be regarded as investigational rather than established melanoma therapies. T-VEC and other intralesional therapies combined with PD-1 antibody Previously referred to as OncoVex GM-CSF, Talimogene laherparepvec (T-VEC) is a genetically altered oncolytic HSV-1 virus. It was engineered by deleting the ICP34.5 gene, which impairs the herpes virus's ability to affect nerve cells while incorporating the gene for human GM-CSF. This modification enables GM-CSF release upon tumor cell lysis, thereby enhancing immune responses. The emergence of ICIs has prompted interest in combining these agents with T-VEC to evaluate potential synergistic effects on immune response. A number of clinical studies have investigated the use of anti-PD-1 antibodies in conjunction with T-VEC. A Phase I trial assessed the combination of pucotenlimab (a PD-1 inhibitor), intrahepatic injection of the oncolytic virus OH2, and radiotherapy (NCT05068453), reporting an ORR of 40.0% (2/5) and a DCR of 80% (4/5) [186]. OrienX010, another HSV-1-derived oncolytic virus, was tested in a Phase I trial in combination with toripalimab for stage IV melanoma patients with liver metastases (NCT04206358). This study found a median PFS of 7.0 months (95% CI: 4.3–9.7 months) and a median OS of 18.6 months (95% CI: 13.4–23.7 months), with a median follow-up of 19.8 months (range: 0.9–29.7). The ORR was 15% (3/20), and the DCR was 50% (10/20) [187]. In a separate study, the combination of pembrolizumab and T-VEC was assessed, revealing an ORR of 57%. Among the 21 participants, 12 achieved either a CR or PR [188]. Additionally, the Voyager V1 (VV1) oncolytic virus, combined with cemiplimab (PD-1 inhibitor) and ipilimumab (CTLA-4 inhibitor), is currently under investigation, although public results are yet to be released (NCT04291105) [189]. Beyond T-VEC, a broader range of intralesional immunotherapies has been investigated in melanoma, particularly for locoregional or in-transit disease. Intralesional interleukin-2 (aldesleukin) has shown durable complete responses in small series of in-transit melanoma and continues to be used in selected locoregional settings [190, 191]. Cancer Care Ontario lists intralesional aldesleukin for in-transit melanoma in patients who are not candidates for surgery or other treatments. More recently, small retrospective and early prospective studies have explored whether intralesional IL-2 may augment systemic checkpoint inhibition or help overcome resistance in selected patients, although this strategy remains non-standard and supported by limited evidence [192, 193]. Other intralesional immunomodulators, including toll-like receptor agonists and additional oncolytic platforms, are also being evaluated as immune-priming partners for PD-1- or CTLA-4-based therapy [194]. From a clinical standpoint, these intralesional approaches are most relevant to patients with locoregional or in-transit disease, rather than disseminated melanoma requiring systemic control. Their value may lie in local disease management or immune priming, but current evidence is insufficient to place them on the same evidentiary level as approved systemic checkpoint blockade. Tumor cell vaccine combined with PD-1 antibody Tumor vaccines, or cancer vaccines, are designed to stimulate immunity against specific tumors. Typically composed of tumor cells or fragments containing tumor-specific antigens, these vaccines activate the body’s immune system upon administration. By triggering targeted immune responses, they aim to overcome immunosuppressive environments and enhance resistance to specific cancers, positioning tumor vaccines as a form of active immunotherapy. A Phase II trial evaluated the combination of the personalized neoantigen vaccine EVX-01 with pembrolizumab or nivolumab (NCT03715985), achieving an ORR of 67%. Notably, no patients experienced grade 3 or higher TRAEs [195]. GEN-009, another personalized neoantigen vaccine, was tested in combination with a PD-1 inhibitor in a clinical study (NCT03633110), demonstrating superior efficacy compared to GEN-009 monotherapy [196]. Other vaccine candidates are also undergoing clinical evaluation. Immunostimulatory cytokine treatment or immunoinhibitory cytokine blockades combined with PD-1 inhibitor N803, an IL-15 superagonist, is under investigation in clinical trials, particularly in combination with PD-1 inhibitors for solid tumors (NCT03228667). While data in non-small cell lung cancer (NSCLC) is substantial, results for melanoma remain unpublished [197]. Infliximab and certolizumab, both TNF-α inhibitors, have been explored in combination with nivolumab (PD-1 inhibitor) and ipilimumab (CTLA-4 antibody). In the certolizumab group of NCT03293784, hepatobiliary disorders were observed in four out of eight patients, and all seven evaluable patients showed an objective response, with four achieving complete responses and three partial responses. In the infliximab cohort, one CR, two PRs, and three instances of progressive disease were reported [198]. Sarilumab, an IL-6 receptor inhibitor, is being evaluated in combination with a multi-checkpoint backbone including ipilimumab, nivolumab, and relatlimab in an ongoing phase II trial (NCT05428007). BORR at 24 weeks was 63.6% (95% CI: 45.1%, 79.6%). Median PFS and OS were not reached [199]. Overall, cytokine-modulating combinations remain early-stage strategies in melanoma, and currently available data are insufficient to define their place relative to approved regimens. Radiotherapy combined with PD-1 antibody Radiotherapy, similar to specific chemotherapeutic agents, can cause immunogenic cell death and strengthen the body's anti-tumor immunity [200]. Most radioimmunotherapy protocols employ stereotactic body radiotherapy (SBRT), a technique that delivers high radiation doses with precision through image-guided and intensity-modulated approaches. In melanoma, however, radiotherapy is generally used for metastatic, oligoprogressive, or palliative indications rather than as routine treatment for primary lesions. The effectiveness of PD-1 inhibitor combination with radiotherapy is being investigated in an ongoing Phase II clinical trial (PORTER-M3) for patients with metastatic mucosal melanoma. 18 patients received nivolumab combined with hypofractionated radiotherapy (25 Gy in five fractions). The primary endpoint was met with an overall response rate of 41.2% (95% CI 18.1%−67.4%), including two complete responses and five partial responses. Median progression-free survival was 4.9 months and median overall survival was 20.1 months. The safety profile was manageable, with grade 3–4 immune-related adverse events occurring in 35.2% of patients and radiation-related toxicities including grade 3 dermatitis and pneumonitis in one patient each. These results suggest that concurrent PD-1 blockade and radiotherapy warrants further investigation as a treatment strategy for this challenging melanoma subtype [201]. Another trial (NCT05498805), which has enrolled 92 eligible patients, is awaiting results [202]. Up to date, radioimmunotherapy should currently be regarded as a clinically relevant investigational strategy in selected advanced melanoma settings rather than a broadly established treatment approach. Fecal microbiota transplant combined with PD-1 antibody The gut microbiome is increasingly recognized as a critical modulator of both innate and adaptive immune responses, influencing the variability in patient responses to anti-PD-1 therapies. The phase II trial NCT03341143 demonstrated that fecal microbiota transplantation (FMT) from patients with durable responses to anti-PD-1 therapy could overcome resistance in recipients with refractory metastatic melanoma, achieving an objective response rate of 20% with associated favorable immune changes in the tumor microenvironment [203]. A phase II trial combining fecal microbiota transplantation (FMT) with pembrolizumab in PD-1 refractory melanoma patients (NCT06030037) has now been withdrawn [201]. A clinical trial is investigating the combination of MRx0518, a strain of Enterococcus gallinarum, with pembrolizumab (NCT03637803) [204, 205], however, the study was terminated early due to company administration issues. Early clinical studies suggest that FMT from donor patients with durable ICI responses may restore sensitivity in a subset of PD-1-refractory melanoma cases, but the available evidence remains limited to small cohorts. Microbiome-directed strategies therefore remain investigational and should currently be regarded as hypothesis-generating rather than practice-changing. Targeted therapy (except for angiogenesis inhibitor) Combined with PD-1 antibody The DREAMseq Phase III trial (NCT02224781) demonstrated that sequencing nivolumab plus ipilimumab before BRAF/MEK inhibitors (dabrafenib plus trametinib) significantly improved two-year overall survival compared with the reverse sequence in treatment-naïve BRAF V600–mutant metastatic melanoma (71.8% versus 51.5%; P = 0.010). This establishes immune therapy as the preferred first-line approach in this population, with targeted therapy reserved for post-progression salvage [206]. Entinostat, which inhibits HDAC, was evaluated in a Phase II clinical trial alongside pembrolizumab (NCT02437136). In anti-PD-(L)1-experienced patients with melanoma, entinostat plus pembrolizumab achieved 18.9% ORR, showed modest activity in anti-PD-(L)1-experienced melanoma [207]. Etrumadenant (AB928), an A2R inhibitor, was explored in a Phase I trial with zimberelimab (NCT03629756) [208]. Rigosertib, a PLK1 inhibitor, was assessed in a Phase II trial combined with pembrolizumab (NCT05764395), which is recruiting. CB-839, a GLS1 inhibitor, was tested in a Phase II trial with nivolumab (NCT02771626), and the combination did not show a pattern of efficacy across different study cohorts [209]. L-NMMA, a nitric oxide synthase inhibitor, was studied in a Phase Ib trial with pembrolizumab (NCT03236935). Belapectin, a galectin-3 inhibitor, was also examined in a Phase I trial with pembrolizumab (NCT02575404) [210]. Final results from these trials are still pending. These regimens should therefore be interpreted as exploratory approaches designed to broaden activity after or beyond standard checkpoint-based therapy. Tumor-Infiltrating Lymphocyte (TIL)-Based therapy and its relationship to immune checkpoint blockade Adoptive cell therapy using tumor-infiltrating lymphocytes (TILs) has emerged as an important addition to the therapeutic landscape of advanced melanoma. In 2024, the FDA granted accelerated approval to Lifileucel (AMTAGVI) for adults with unresectable or metastatic melanoma previously treated with a PD-1-blocking antibody and, for BRAF V600-mutant disease, a BRAF inhibitor with or without a MEK inhibitor. In NCT02360579, the ORR was 31.4% (complete response, 5.9%; partial response, 25.5%). This approval is noteworthy because melanoma remains the first solid tumor in which a TIL product has entered routine regulatory practice [211]. Across currently established ICI-based regimens for advanced melanoma, the most mature evidence supports PD-1-based therapy and dual checkpoint blockade. Compared with dacarbazine, nivolumab substantially improves ORR, PFS, and long-term survival. In turn, nivolumab plus ipilimumab provides the longest median overall survival among widely used regimens, albeit with substantially greater toxicity than PD-1 monotherapy. By contrast, most PD-1-based combinations summarized in Table 2, including anti-angiogenic agents, intralesional therapies, microbiome-directed interventions, cytokine modulation, and other targeted agents, are supported primarily by phase I/II data, often with small sample sizes, selected patient populations, and immature OS readouts. Therefore, numerical improvements in ORR or PFS in early studies should not be interpreted as equivalent to the level of evidence supporting approved melanoma immunotherapies. Clinical picture of PD-L1 inhibitor drugs Advancements in foundational research on immune checkpoints have driven significant progress in the development of immune checkpoint blockade therapies. PD-L1, a key ligand in the PD-1/PD-L1 axis, has emerged as a critical therapeutic target in oncology. Currently, four PD-L1 inhibitors (atezolizumab, durvalumab, avelumab, cosibelimab) have received FDA approval for the treatment of various solid malignancies. Notably, among these approved indications, atezolizumab is approved solely for the combination regimen in metastatic melanoma (in combination with cobimetinib and vemurafenib in patients with BRAF V600 mutation-positive disease), and has not yet received approval for monotherapy or alternative combination strategies in this malignancy [212] (Table 3). Melanoma remains an unaddressed therapeutic domain for PD-L1 blockade. Current clinical trials exploring the efficacy of PD-L1 monoclonal antibodies in combination with other therapies are noteworthy (Table 4).Table 3Clinical trials of PD-L1 inhibitors monotherapyDrugsNCT numberConditionsPhasesNumber of ParticipantsAEsEfficacyall grade TRAEs >/= G3 TRAEsORRDCRPFSOSDurvalumab (PD-L1 inhibitor)NCT01693562Advanced Solid Tumors1/2102260–70%10–15%10–15%35–45%10–15%the median PFS (2.5–3.5 months [95% CI, 1.8–4.2])30–35%the median OS (8–10 months [95% CI, 6.5–11.5])Atezolizumab (PD-L1 inhibitor)NCT01375842Locally Advanced or Metastatic Solid Tumors166160%16%15–20%40–50%the median PFS (2.0–4.0 months)the median OS (6.0–12.0 months)Avelumab(PD-L1 inhibitor)NCT01772004previously treated metastatic melanoma1b5139 patients (76.5%),infusion-related reaction (25.5%), fatigue (17.6%), and chills (11.8%)4 patients(7.8%)11/51(21.6%)NAMedian PFS was 3.1 mo (95% CI 1.4–6.3)Median OS was 18.5 mo (95% CI 9.3–NE)INCB086550(an oral PD-L1 inhibitor)NCT04629339advanced solid tumors1138 > 20% patients18 patients (13.0%)12/138(8.6%)NANANAINCB086550(an oral PD-L1 inhibitor)NCT03762447advanced solid tumors17946 patients(58.2%)10 patients (12.7%)8/68(11.8%)13/68(19.1%)NANAINCB099280(orally administered PD-L1 inhibitor)NCT04242199previously treated metastatic melanoma173 > 20% of patients: decreased appetite, fatigue, nausea, anemia, diarrhea, asthenia, and vomiting6.80%NANANANATable 4Clinical trials of PD-L1 inhibitors combination therapyDrugsNCT numberConditionsPhasesNumber of ParticipantsAEsEfficacyall grade TRAEs >/= G3 TRAEsORRDCRPFSOSAtezolizumab (A,PD-L1 inhibitor), cobimetinib (C), and vemurafenib (V)NCT03625141BRAFV600 mutation–positive melanoma with central nervous system (CNS) metastases265lipase increased (27%) and blood CPK increased (17%)70%25/65(38%)NAMedian PFS,5.1 months (95% CI 3.7–6.9)The median OS,13,4 months (95% CI, 10.7–16.9)NCT02902029advanced BRAFV600-positive melanoma2135, Arm A (n = 69) or Arm B (n = 66)NA55% in Arm A and 64% in Arm B51/69(74%)in Arm A and 49/66(74%) in Arm B68/69(99%)in Arm A and 65/66(74%) in Arm Bth median PFS 13.9 months (95% CI 9.9–16.6) in Arm A,5.9 months(95% CI 5.4–8.3) in Arm BNAAtezolizumab(PD-L1 inhibitor) plus bevacizumab(VEGF-A inhibitor)NCT04091217unresectable or metastatic mucosal melanoma24390.70%25.60%18/40(45%)26/40(65%)The median PFS was 8.2 months (95% CI, 2.7–9.6)The median OS was not reached (NR) (95% CI, 14.4-NR)TQB2450(PD-L1 inhibitor) Combined With AnlotinibNCT03991975advanced acral melanoma1b1995%31.60%4/19(21%)14/19(73.7%)median PFS time was 5.5 months (95% CI, 2.8 months to not reached)The median OS was 20.3 months (95% CI, 10.2 months to not reached)Durvalumab(MEDI4736,anti-PD-L1) with BRAF (dabrafenib) and/or MEK (trametinib) inhibitorsNCT02027961Advanced Melanoma150,BRAF mutant in Cohort A (M + D + T)n = 24; BRAF WT in Cohort B (M + T) n = 20,or Cohort C (sequential T → M)n = 696% in A,90% in B,100% in C33% in A,40% in B,17% in C16/21(76%) in A,3/14(21.4%) in B,3/6(50%) in C21/21(100%) in A,9/14(64.3%) in B,4/6(66.7%) in CNANAceralasertib (AZD6738, oral inhibitor of the serine/threonine protein kinase ATR) in combination with durvalumab(PD-L1 inhibitor)NCT03780608metastatic melanoma who have failed prior anti-PD-1 therapy230anemia (n = 23, 76.7%), anorexia (n = 20, 66.7%) and thrombocytopenia (n = 19, 63.3%)33%9/30(30.0%)19/30(63.3%)th median PFS 7.1 months (95% CI 3.6–10.6),the median OS was 14.2 months (95% CI, 9.3–19.1)Atezolizumab(PD-L1 inhibitor) Plus NT-I7(long-acting human IL-7)NCT03901573anti-PD-1/PD-L1 naïve or relapsed/refractory (R/R) high-risk skin cancers1b/2a1669%31%011/16(69%)NANAEnvafolimab(PD-L1 inhibitor) Combined With Recombinant Human Endostatin and First-line ChemotherapyNCT06041724Advanced Mucosal Melanoma246NANANANANANA Table 3Clinical trials of PD-L1 inhibitors monotherapyDrugsNCT numberConditionsPhasesNumber of ParticipantsAEsEfficacyall grade TRAEs >/= G3 TRAEsORRDCRPFSOSDurvalumab (PD-L1 inhibitor)NCT01693562Advanced Solid Tumors1/2102260–70%10–15%10–15%35–45%10–15%the median PFS (2.5–3.5 months [95% CI, 1.8–4.2])30–35%the median OS (8–10 months [95% CI, 6.5–11.5])Atezolizumab (PD-L1 inhibitor)NCT01375842Locally Advanced or Metastatic Solid Tumors166160%16%15–20%40–50%the median PFS (2.0–4.0 months)the median OS (6.0–12.0 months)Avelumab(PD-L1 inhibitor)NCT01772004previously treated metastatic melanoma1b5139 patients (76.5%),infusion-related reaction (25.5%), fatigue (17.6%), and chills (11.8%)4 patients(7.8%)11/51(21.6%)NAMedian PFS was 3.1 mo (95% CI 1.4–6.3)Median OS was 18.5 mo (95% CI 9.3–NE)INCB086550(an oral PD-L1 inhibitor)NCT04629339advanced solid tumors1138 > 20% patients18 patients (13.0%)12/138(8.6%)NANANAINCB086550(an oral PD-L1 inhibitor)NCT03762447advanced solid tumors17946 patients(58.2%)10 patients (12.7%)8/68(11.8%)13/68(19.1%)NANAINCB099280(orally administered PD-L1 inhibitor)NCT04242199previously treated metastatic melanoma173 > 20% of patients: decreased appetite, fatigue, nausea, anemia, diarrhea, asthenia, and vomiting6.80%NANANANA Clinical trials of PD-L1 inhibitors monotherapy 10–15% the median PFS (2.5–3.5 months [95% CI, 1.8–4.2]) 30–35% the median OS (8–10 months [95% CI, 6.5–11.5]) Table 4Clinical trials of PD-L1 inhibitors combination therapyDrugsNCT numberConditionsPhasesNumber of ParticipantsAEsEfficacyall grade TRAEs >/= G3 TRAEsORRDCRPFSOSAtezolizumab (A,PD-L1 inhibitor), cobimetinib (C), and vemurafenib (V)NCT03625141BRAFV600 mutation–positive melanoma with central nervous system (CNS) metastases265lipase increased (27%) and blood CPK increased (17%)70%25/65(38%)NAMedian PFS,5.1 months (95% CI 3.7–6.9)The median OS,13,4 months (95% CI, 10.7–16.9)NCT02902029advanced BRAFV600-positive melanoma2135, Arm A (n = 69) or Arm B (n = 66)NA55% in Arm A and 64% in Arm B51/69(74%)in Arm A and 49/66(74%) in Arm B68/69(99%)in Arm A and 65/66(74%) in Arm Bth median PFS 13.9 months (95% CI 9.9–16.6) in Arm A,5.9 months(95% CI 5.4–8.3) in Arm BNAAtezolizumab(PD-L1 inhibitor) plus bevacizumab(VEGF-A inhibitor)NCT04091217unresectable or metastatic mucosal melanoma24390.70%25.60%18/40(45%)26/40(65%)The median PFS was 8.2 months (95% CI, 2.7–9.6)The median OS was not reached (NR) (95% CI, 14.4-NR)TQB2450(PD-L1 inhibitor) Combined With AnlotinibNCT03991975advanced acral melanoma1b1995%31.60%4/19(21%)14/19(73.7%)median PFS time was 5.5 months (95% CI, 2.8 months to not reached)The median OS was 20.3 months (95% CI, 10.2 months to not reached)Durvalumab(MEDI4736,anti-PD-L1) with BRAF (dabrafenib) and/or MEK (trametinib) inhibitorsNCT02027961Advanced Melanoma150,BRAF mutant in Cohort A (M + D + T)n = 24; BRAF WT in Cohort B (M + T) n = 20,or Cohort C (sequential T → M)n = 696% in A,90% in B,100% in C33% in A,40% in B,17% in C16/21(76%) in A,3/14(21.4%) in B,3/6(50%) in C21/21(100%) in A,9/14(64.3%) in B,4/6(66.7%) in CNANAceralasertib (AZD6738, oral inhibitor of the serine/threonine protein kinase ATR) in combination with durvalumab(PD-L1 inhibitor)NCT03780608metastatic melanoma who have failed prior anti-PD-1 therapy230anemia (n = 23, 76.7%), anorexia (n = 20, 66.7%) and thrombocytopenia (n = 19, 63.3%)33%9/30(30.0%)19/30(63.3%)th median PFS 7.1 months (95% CI 3.6–10.6),the median OS was 14.2 months (95% CI, 9.3–19.1)Atezolizumab(PD-L1 inhibitor) Plus NT-I7(long-acting human IL-7)NCT03901573anti-PD-1/PD-L1 naïve or relapsed/refractory (R/R) high-risk skin cancers1b/2a1669%31%011/16(69%)NANAEnvafolimab(PD-L1 inhibitor) Combined With Recombinant Human Endostatin and First-line ChemotherapyNCT06041724Advanced Mucosal Melanoma246NANANANANANA Clinical trials of PD-L1 inhibitors combination therapy Angiogenesis inhibitor combined with PD-L1 antibody Abnormal angiogenesis can hinder the anti-tumor immune response. A number of clinical trials have explored the synergistic effects of combining angiogenesis inhibitors with PD-L1 antibodies. Trials investigating the combination of atezolizumab with angiogenesis inhibitors have shown preliminary activity. Two studies evaluated the efficacy of atezolizumab (A), cobimetinib (C, a MEK inhibitor), and vemurafenib (V, a B-Raf inhibitor) (NCT03625141, NCT02902029). One trial, involving 65 BRAFV600 mutation-positive melanoma patients with central nervous system (CNS) metastases, reported an ORR of 38% and a median PFS of 5.1 months (95% CI 3.7–6.9) [213]. Another trial, involving 135 advanced BRAFV600-positive melanoma patients, randomized participants into two arms: Arm A (n = 69) and Arm B (n = 66). Grade 3/4 AEs occurred in 55% of patients in Arm A and 64% in Arm B, with treatment discontinuation due to AEs in 10% and 12% of patients, respectively. Median PFS was significantly longer in Arm A compared to Arm B (HR 0.55; 95% CI 0.37–0.84; P = 0.001). ORR and DCR were higher in Arm A before crossover and in Arm B post-crossover. OS did not differ significantly between the arms (HR 1.22; 95% CI 0.69–2.16; P = 0.389) [214]. Bevacizumab, a VEGF-A antibody, was evaluated in a phase II trial combining atezolizumab with bevacizumab for patients with unresectable or metastatic mucosal melanoma (NCT04091217). This combination achieved an ORR of 45.0% (95% CI, 29.3–61.5), including one CR and 17 PRs, and a DCR of 65.0% (95% CI, 48.3–79.4). Median PFS was 8.2 months (95% CI, 2.7–9.6) [215]. Additionally, other PD-L1 monoclonal antibodies combined with angiogenesis inhibitors are under investigation in ongoing clinical trials, further phase 3 trials are necessary to validate the effectiveness of these combination therapies [216–218]. Immunostimulatory cytokine treatment combined with PD-L1 antibody Cytokines, including GM-CSF, IFN-α, IL-2, IL-7, IL-12, IL-15, IL-18, and IL-21, exhibit antitumor activity by stimulating immune responses, inhibiting tumor cell proliferation, or inducing apoptosis [219]. Additionally, neutralizing cytokines such as TGF-β and IL-6 can enhance anti-tumor immunity [220]. A phase II trial explored the combination of atezolizumab and long-acting human IL-7 (NT-I7) in patients with anti-PD-1/PD-L1 naive or relapsed/refractory (R/R) high-risk skin cancers (NCT03901573), though the efficacy was limited [221]. Another ongoing study is investigating the combination of envafolimab with recombinant human endostatin and first-line chemotherapy, with results yet to be reported (NCT06041724) [222]. Clinical picture of CTLA-4 inhibitor drugs As one of the earliest identified immune checkpoints, CTLA-4 has been the focus of substantial research for the development of targeted immune checkpoint inhibitors. Ipilimumab has firstly received FDA approval for the treatment of melanoma in 2011, demonstrated improved overall survival as monotherapy in the phase III MDX010-20 trial (median overall survival 10.1 months vs 6.4 months with gp100 vaccine; NCT00094653) [86, 223]. the CA184-024 trial (NCT00324155) extended this survival advantage to the first-line setting, demonstrating that the combination of ipilimumab (10 mg/kg) plus dacarbazine significantly improved median OS compared with dacarbazine plus placebo (11.2 vs. 9.1 months) in patients with previously untreated metastatic disease [223]. Subsequently, in a phase 3 adjuvant trial (NCT00636168) to evaluate the efficacy and safety of ipilimumab as adjuvant therapy following complete resection of high-risk stage III melanoma, ipilimumab showed significantly prolonged recurrence-free survival (5-year rate, 40.8% vs. 30.3%; HR, 0.76; P < 0.001) and OS (5-year rate, 65.4% vs. 54.4%; HR, 0.72; P = 0.001) [224, 225]. It is now predominantly used in combination with nivolumab. Tremelimumab monotherapy has demonstrated inferior efficacy compared with ipilimumab in melanoma and consequently failed to obtain FDA approval for this indication [226] (Table 5). Similar to PD-1 and PD-L1 inhibitors, many CTLA-4-targeting monoclonal antibodies have shown improved safety and efficacy when combined with other therapies, compared to monotherapy (Table 6).Table 5Clinical trials of CTLA-4 inhibitors monotherapyDrugsNCT numberConditionsPhasesNumber of ParticipantsAEsEfficacyall grade TRAEs >/= G3 TRAEsORRDCRPFSOSTremelimumab (CTLA-4inhibitor)NCT00378482Melanoma23710.8%10.8%NANA51.4%27%Ipilimumab (CTLA-4 inhibitor) vs gp100NCT00094653metastatic melanoma3ipilimumab plus gp100 (403 patients), ipilimumab alone (137), or gp100 alone (136)NA10 to 15% of patients treated with ipilimumab and in 3% treated with gp100 alone10.9%(ipilimumab) vs 1.5%(gp100)29%(ipilimumab) vs (gp100)2.8 monthsThe median overall survival was 10.1 months in ipilimumab alone, 10.0 months in ipilimumab plus gp100, 6.4 months in gp100 aloneIpilimumab (CTLA-4 inhibitor) plus dacarbazine vs dacarbazineNCT00324155untreated metastatic melanoma3502NA56.3% vs 27.5%15.2% vs 10.3%33.2% vs 30.2%19.3 months vs 8.1 months11.2 months vs. 9.1 monthsIpilimumab (CTLA-4 inhibitor)NCT00636168High Risk Stage III Melanoma3945,471 in A(IPI),474 in B(placebo)93.63% in A,80.59% in B54.56% in A,27% in BNANANANABA3071(CTLA-4 inhibitor)NCT05180799Solid Tumor1/2320NANANANANANABotensilimab (AGEN1181,CTLA-4 inhibitor)NCT05529316Advanced Melanoma2220NANANANANANATable 6Clinical trials of CTLA-4 inhibitors combination therapyDrugsNCT numberConditionsPhasesNumber of ParticipantsAEsEfficacyall grade TRAEs >/= G3 TRAEsORRDCRPFSOSNivolumab(PD-1 inhibitor) and Ipilimumab(CTLA-4 inhibitor)NCT01024231advanced melanoma153 in A(concurrent therapy with nivolumab and ipilimumab) and 33 in B(sequenced treatment)NA53% in A,18% in B21/53(40%) in A,7/33(20%) in B34/53(65%) in ANANANivolumab(PD-1 inhibitor) and ipilimumab(CTLA-4 inhibitor) versus ipilimumab(CTLA-4 inhibitor)NCT01927419untreated melanoma172 in A(nivo + ipi),37 in B(ipi)NA54% in A, 24% in B44/72(61%) in A, 4/37(11%) in BNAThe median PFS was not reached in A, and was 4.4 months(95%CI 0.23 to 0.68) in BNANivolumab(PD-1 inhibitor) and Ipilimumab(CTLA-4 inhibitor)NCT02320058melanoma metastatic to the brain294NA55%53/94(56%)55/94(58%)NANAHBM4003(an anti-CTLA-4 heavy chain only monoclonal antibody)in combination with toripalimab(JS001,T,PD-1 inhibitor)NCT04727164advanced melanoma and other solid tumors14090%25%33.3%NANANAIBI310(CTLA-4 inhibitor) monotherapy or in combination with sintilimab(PD-1 inhibitor)NCT03545971advanced melanoma1a/1b10 in Part A (IBI310),17 in Part B and C (IBI310 + SIN)90% in Part A,76% in Part B and C0 in Part A,6% in Part B and C0 in Part A,2/10(20%) in Part B5/10(50%) in Part A,7/10(70%) in Part BNANAXmAb23104 (PD-1 X ICOS) and XmAb22841 (CTLA-4 X LAG3) combinationNCT05695898metastatic melanoma refractory to prior immune checkpoint inhibitor therapy with and without CNS disease1b/246NANANANANANAXmAb®22,841(pavunalimab,CTLA-4 X LAG3 Bispecific Antibody) Monotherapy & in Combination with Pembrolizumab(anti PD-1)NCT03849469advanced solid tumors178NANANANANANABCD-217:Nurulimab(CTLA-4 inhibitor) + Prolgolimab(PD-1 inhibitor)NCT05751928Resectable Stage III Skin Melanoma3410NANANANANANAipilimumab(CTLA-4 inhibitor) in combination with talimogene laherparepvec(oncolytic viral)NCT01740297melanoma21926%NA9/18(50%)NANANACoxsackievirus A21(novel bio-selected oncolytic) and ipilimumabNCT02307149advanced melanoma patients previously treated with anti-PD-1 blockade therapy1b13NA7.70%3/8(38.0%)7/8 (88%)NANAHF10(replication-competent HSV-1 oncolytic virus) and ipilimumab(CTLA-4 inhibitor) combinationNCT02272855stage IIIB-IV unresectable or metastatic melanoma246NA37%18/44(41%)30/44(68%)median PFS was 19 monthsmedian overall survival was 21.8 monthsintratumoral ipilimumab plus IL-2NCT01672450advanced melanoma112NANA40% (95% CI, 10%−70%)NANANAIpilimumab(CTLA-4 inhibitor) + Radiation TherapyNCT01449279melanoma222100%40.90%11/22(50%)NAmedian PFS 26 weeks (95% CI,9 to 50)median OS 107 weeks (95% CI,7 to 214)Ipilimumab(CTLA- inhibitor) combined with stereotactic radiosurgeryNCT02662725melanoma patients with brain metastases257NANANA28/57(49%)NAmedian survival time was 13.2 monthsIpilimumab(CTLA-4 inhibitor) and Local Radiation TherapyNCT01769222Recurrent Melanoma, Non-Hodgkin Lymphoma, Colon, or Rectal Cancer1/23,3 in A(ipi),0 in B(ipi + radiation)33.3% in A,0 in B00000 Table 5Clinical trials of CTLA-4 inhibitors monotherapyDrugsNCT numberConditionsPhasesNumber of ParticipantsAEsEfficacyall grade TRAEs >/= G3 TRAEsORRDCRPFSOSTremelimumab (CTLA-4inhibitor)NCT00378482Melanoma23710.8%10.8%NANA51.4%27%Ipilimumab (CTLA-4 inhibitor) vs gp100NCT00094653metastatic melanoma3ipilimumab plus gp100 (403 patients), ipilimumab alone (137), or gp100 alone (136)NA10 to 15% of patients treated with ipilimumab and in 3% treated with gp100 alone10.9%(ipilimumab) vs 1.5%(gp100)29%(ipilimumab) vs (gp100)2.8 monthsThe median overall survival was 10.1 months in ipilimumab alone, 10.0 months in ipilimumab plus gp100, 6.4 months in gp100 aloneIpilimumab (CTLA-4 inhibitor) plus dacarbazine vs dacarbazineNCT00324155untreated metastatic melanoma3502NA56.3% vs 27.5%15.2% vs 10.3%33.2% vs 30.2%19.3 months vs 8.1 months11.2 months vs. 9.1 monthsIpilimumab (CTLA-4 inhibitor)NCT00636168High Risk Stage III Melanoma3945,471 in A(IPI),474 in B(placebo)93.63% in A,80.59% in B54.56% in A,27% in BNANANANABA3071(CTLA-4 inhibitor)NCT05180799Solid Tumor1/2320NANANANANANABotensilimab (AGEN1181,CTLA-4 inhibitor)NCT05529316Advanced Melanoma2220NANANANANANA Clinical trials of CTLA-4 inhibitors monotherapy Tremelimumab (CTLA-4 inhibitor) Table 6Clinical trials of CTLA-4 inhibitors combination therapyDrugsNCT numberConditionsPhasesNumber of ParticipantsAEsEfficacyall grade TRAEs >/= G3 TRAEsORRDCRPFSOSNivolumab(PD-1 inhibitor) and Ipilimumab(CTLA-4 inhibitor)NCT01024231advanced melanoma153 in A(concurrent therapy with nivolumab and ipilimumab) and 33 in B(sequenced treatment)NA53% in A,18% in B21/53(40%) in A,7/33(20%) in B34/53(65%) in ANANANivolumab(PD-1 inhibitor) and ipilimumab(CTLA-4 inhibitor) versus ipilimumab(CTLA-4 inhibitor)NCT01927419untreated melanoma172 in A(nivo + ipi),37 in B(ipi)NA54% in A, 24% in B44/72(61%) in A, 4/37(11%) in BNAThe median PFS was not reached in A, and was 4.4 months(95%CI 0.23 to 0.68) in BNANivolumab(PD-1 inhibitor) and Ipilimumab(CTLA-4 inhibitor)NCT02320058melanoma metastatic to the brain294NA55%53/94(56%)55/94(58%)NANAHBM4003(an anti-CTLA-4 heavy chain only monoclonal antibody)in combination with toripalimab(JS001,T,PD-1 inhibitor)NCT04727164advanced melanoma and other solid tumors14090%25%33.3%NANANAIBI310(CTLA-4 inhibitor) monotherapy or in combination with sintilimab(PD-1 inhibitor)NCT03545971advanced melanoma1a/1b10 in Part A (IBI310),17 in Part B and C (IBI310 + SIN)90% in Part A,76% in Part B and C0 in Part A,6% in Part B and C0 in Part A,2/10(20%) in Part B5/10(50%) in Part A,7/10(70%) in Part BNANAXmAb23104 (PD-1 X ICOS) and XmAb22841 (CTLA-4 X LAG3) combinationNCT05695898metastatic melanoma refractory to prior immune checkpoint inhibitor therapy with and without CNS disease1b/246NANANANANANAXmAb®22,841(pavunalimab,CTLA-4 X LAG3 Bispecific Antibody) Monotherapy & in Combination with Pembrolizumab(anti PD-1)NCT03849469advanced solid tumors178NANANANANANABCD-217:Nurulimab(CTLA-4 inhibitor) + Prolgolimab(PD-1 inhibitor)NCT05751928Resectable Stage III Skin Melanoma3410NANANANANANAipilimumab(CTLA-4 inhibitor) in combination with talimogene laherparepvec(oncolytic viral)NCT01740297melanoma21926%NA9/18(50%)NANANACoxsackievirus A21(novel bio-selected oncolytic) and ipilimumabNCT02307149advanced melanoma patients previously treated with anti-PD-1 blockade therapy1b13NA7.70%3/8(38.0%)7/8 (88%)NANAHF10(replication-competent HSV-1 oncolytic virus) and ipilimumab(CTLA-4 inhibitor) combinationNCT02272855stage IIIB-IV unresectable or metastatic melanoma246NA37%18/44(41%)30/44(68%)median PFS was 19 monthsmedian overall survival was 21.8 monthsintratumoral ipilimumab plus IL-2NCT01672450advanced melanoma112NANA40% (95% CI, 10%−70%)NANANAIpilimumab(CTLA-4 inhibitor) + Radiation TherapyNCT01449279melanoma222100%40.90%11/22(50%)NAmedian PFS 26 weeks (95% CI,9 to 50)median OS 107 weeks (95% CI,7 to 214)Ipilimumab(CTLA- inhibitor) combined with stereotactic radiosurgeryNCT02662725melanoma patients with brain metastases257NANANA28/57(49%)NAmedian survival time was 13.2 monthsIpilimumab(CTLA-4 inhibitor) and Local Radiation TherapyNCT01769222Recurrent Melanoma, Non-Hodgkin Lymphoma, Colon, or Rectal Cancer1/23,3 in A(ipi),0 in B(ipi + radiation)33.3% in A,0 in B00000 Clinical trials of CTLA-4 inhibitors combination therapy Immune checkpoint blockades combined with CTLA-4 inhibitor and PD-1/PD-L1 antibody In clinical practice, the combination of ipilimumab and nivolumab has become a common therapeutic regimen. Key immune checkpoints, CTLA-4 and PD-1, regulate T-cell activation using separate mechanisms. Enhancing the host's antitumor immune response can be achieved by targeting both CTLA-4 and PD-1/PD-L1 pathways at the same time. There is increasing support for the idea that dual inhibition of PD-1/PD-L1 and CTLA-4 pathways leads to better outcomes in certain malignancies. Long-term follow-up data from the phase III CheckMate 067 trial confirmed that median overall survival was 71.9 months with nivolumab plus ipilimumab, further supporting its use as a standard-of-care first-line regimen (NCT01844505) [174]. A phase I study CheckMate 004 (NCT01024231) involving 53 patients treated concurrently with nivolumab and ipilimumab demonstrated an ORR of 40%, whereas the ORR for the 33 patients receiving sequenced treatment was 20% [227]. In another comparison of nivolumab and ipilimumab versus ipilimumab alone (CheckMate 069, NCT01927419), 72 patients were assigned to arm A (nivo + ipi) and 37 to arm B (ipi). For patients with BRAF wild-type tumors, the combination therapy group had a confirmed ORR of 61% (44/72), while the monotherapy group had an ORR of 11% (4/37) (P < 0.001). In the combination therapy group, 22% (16 out of 72) of patients achieved complete responses, whereas no complete responses were seen in the monotherapy group. The median progression-free survival was not reached for the combination therapy, but it was 4.4 months for those receiving ipilimumab alone [228]. Additional studies such as CheckMate 204 (NCT02320058) have demonstrated that ipilimumab and nivolumab together exhibit synergistic effects on the immune response against advanced melanoma, surpassing the efficacy of monotherapy [229, 230]. Other CTLA-4 inhibitors, such as HBM4003 (an anti-CTLA-4 heavy chain-only monoclonal antibody), are also being tested in combination with PD-1 inhibitors, including toripalimab (JS001, PD-1 inhibitor) in NCT04727164 [231], and IBI310 (CTLA-4 inhibitor), either alone or with sintilimab (PD-1 inhibitor) in NCT03545971 [232]. In addition to combination therapies, numerous studies focus on the development of multi-targeted drugs, some of which are progressing into clinical trials. XmAb23104, a dual-target antibody against PD-1 and ICOS, and XmAb22841, a dual-target antibody targeting CTLA-4 and LAG-3, are among these. The combination of XmAb23104 and XmAb22841 is being explored in NCT05695898, while NCT03849469 investigates XmAb22841 in combination with pembrolizumab [233]. T-VEC and other intralesional therapies combined with CTLA-4 antibody Several clinical trials have investigated the combination of anti-CTLA-4 antibodies with T-VEC. A Phase II study evaluated the combination of ipilimumab and talimogene laherparepvec (NCT01740297), yielding an ORR of 50.0% (9/18) [234]. In a Phase I trial, Coxsackievirus A21, a novel bio-selected oncolytic virus, was tested alongside ipilimumab in advanced melanoma patients previously treated with anti-PD-1 blockade, resulting in an ORR of 38% and a DCR of 88% (NCT02307149) [235]. Additionally, the replication-competent HSV-1 oncolytic virus HF10 was examined in combination with ipilimumab (NCT02272855), demonstrating significant anti-cancer effects when combined with immune checkpoint inhibitors [236]. For other intralesional therapies, a Phase I clinical trial evaluated intratumoral ipilimumab plus IL-2 in 12 patients with unresectable stage III/IV melanoma. The combination was well tolerated with no dose-limiting toxicities. Notably, local response occurred in 67% of injected lesions, while abscopal response in non-injected lesions was observed in 89% of patients [237]. The result indicated that intratumoral ipilimumab combined with IL-2 is feasible and can induce responses in both injected and non-injected lesions in patients with advanced melanoma. Radiotherapy combined with CTLA-4 antibody Further studies are exploring the combination of ipilimumab with radiotherapy, particularly in comparison to PD-1 inhibitors. In a Phase II clinical trial for melanoma, 22 participants received ipilimumab plus radiation therapy (NCT01449279). The ORR was 50%, with 11 patients achieving PR. The median PFS was 26 weeks (95% CI, 9–50), and the median OS was 107 weeks (95% CI, 7–214), indicating substantial therapeutic benefit. However, 100% of participants experienced TRAEs, with 40.9% reporting grade 3 or higher events [238]. Another Phase II trial (NCT02662725) assessing the combination of ipilimumab and stereotactic radiosurgery in melanoma patients with brain metastases reported an ORR of 49% and a median OS of 13.2 months [239]. Clinical picture of LAG-3 inhibitor drugs Clinical trials targeting the LAG-3 immune checkpoint are actively advancing in melanoma treatment. Relatlimab (BMS-986016), the first anti-LAG-3 monoclonal antibody approved by the FDA in March 2022, is used in combination with nivolumab for patients over 12 years old with unresectable or metastatic melanoma, based on positive results from the phase II/III RELATIVITY-047 trial (NCT03470922). This study, involving 714 untreated melanoma patients, demonstrated that the combination therapy significantly improved both the ORR (43% vs 33%) and PFS (10.1 months vs 4.6 months) compared to nivolumab monotherapy [94, 240]. Notably, the RELATIVITY-047 trial demonstrated that the combination of relatlimab (anti-LAG-3) and nivolumab achieved comparable efficacy to nivolumab plus ipilimumab, but with a markedly improved safety profile, suggesting that LAG-3 blockade may serve as a less toxic alternative to CTLA-4 blockade in combination strategies [241]. In another phase II trial (NCT03743766) involving 22 patients with advanced melanoma, relatlimab plus nivolumab yielded an ORR of 4.5% and a DCR of 54.5%, with one patient achieving a PR and 12 showing SD. Safety concerns included grade 3 or higher TRAEs in 25% of participants [242]. In the resectable melanoma trial (NCT02519322), the combination showed significant synergy, with a 57% pCR rate and a 70% overall pathologic response rate in the intent-to-treat (ITT) population. Notably, no grade 3 or 4 TRAEs were observed [64]. Beyond relatlimab, several other anti-LAG-3 antibodies are in clinical development. In a phase I study (NCT03005782, n = 98), Fianlimab (REGN3767), a fully human IgG4 monoclonal antibody targeting LAG-3, demonstrated encouraging antitumor effects, achieving an ORR of 61.2% and a median PFS of 15.3 months (95% CI: 9.4-NE). A phase III trial (NCT05608291) is underway to compare fianlimab plus or minus cemiplimab (PD-1 antibody) with pembrolizumab in advanced melanoma patients (n = 1530) [243]. LBL007, another fully human IgG4 anti-LAG-3 mAb, was tested in combination with toripalimab (anti-PD-1) in a phase I study (NCT04640545) for patients with unresectable or metastatic melanoma. Among 32 evaluable patients, the combination achieved an ORR of 12.5% and a DCR of 53.1% [244]. Ieramilimab (LAG525), a humanized IgG4 anti-LAG-3 mAb, was assessed in a phase I/II trial (NCT02460224) as a monotherapy or combined with spartalizumab (PD-1 antibody) for advanced malignancies, including melanoma. No CR or PR was observed with monotherapy, while the combination resulted in one CR and 11 PRs, yielding an ORR of 10% [245]. Eftilagimod alpha (IMP321), a recombinant LAG-3Ig fusion protein, demonstrated antitumor activity in combination with pembrolizumab in a phase I study (NCT02676869), achieving an ORR of 50% with no dose-limiting toxicities (DLTs) or TRAEs ≥ grade 3 [246]. Other anti-LAG-3 monoclonal antibodies, IBI110 and INCAGN02385, are also undergoing clinical evaluation (NCT05572463, NCT03538028, NCT04370704) [247]. Additionally, bispecific antibodies targeting both PD-1 and LAG-3, RO7247669 and INCA32459, are being tested in ongoing trials for advanced or metastatic solid tumors, including melanoma (NCT05116202, NCT04140500, NCT05577182). The Morpheus-Melanoma trial (NCT05116202) is a phase 1b/2, randomized, open-label, multicenter umbrella study that evaluated the neoadjuvant use of tobemstomig, a PD-1/LAG-3 bispecific antibody, in patients with resectable stage III melanoma. Tobemstomig exhibited a markedly improved safety profile compared with nivolumab plus ipilimumab, with grade 3 or higher treatment-related adverse events (TRAEs) occurring in only 2.5% (1/40) versus 22.7% (5/22) of patients, and no discontinuations due to TRAEs (0% vs. 13.6%) [248]. The trial provides proof-of-concept for bispecific antibody-based neoadjuvant immunotherapy in melanoma (Table 7).Table 7Clinical trials of other immune checkpoint inhibitorsDrugsNCT numberConditionsPhasesNumber of ParticipantsAEsEfficacyall grade TRAEs >/= G3 TRAEsORRDCRPFSOSnivolumab (anti PD-1) with relatlimab (anti LAG-3)NCT03470922first-line advanced melanoma3714, RELA + NIVO FDC (n = 355) or NIVO (n = 359)NARELA + NIVO FDC group (18.9%), NIVO (9.7%RELA + NIVO FDC group (43%), NIVO (33%)NAthe median PFS in the RELA + NIVO group (10.1 months [95% CI, 6.4–15.7]),the median PFS in the NIVO group (4.6 months [95% CI, 3.4–5.6]the median OS in the RELA + NIVO group NR,the median OS in the NIVO group (34 months [95% CI, 25.2–NR]NCT03743766first-line advanced melanoma222proliferative fibrosis(50%), neovascularization(35%), plasma cells(26.3%25%1/22(4.5%)13/22(59%)NANANCT02519322resectable clinical stage III melanoma230NA017/30(57%)NANAthe 1 -year OS was 95%fianlimab (anti-LAG-3) and cemiplimab (anti-PD-1)NCT03005782advanced melanoma198NA43.90%60/98(61.2%)NAthe median PFS was 15.3 months(95% CI: 9.4–NE)NAfianlimab(anti-LAG-3) With Cemiplimab(anti-PD-1) VS Pembrolizumab(anti-PD-1)NCT05608291Delaying Melanoma31530NANANANANANALBL-007 (an anti-LAG-3 antibody) in combination with toripalimab (an anti-PD-1 antibody) or LBL-007 in combination with toripalimab and axitinibNCT04640545advanced melanoma1Part A LBL-007 plus toripalimab:68;Part B LBL-007 plus toripalimab with axitinib:NAPart A:27.9%; PartB:45.5%Part A:13/55(23.6%);PartB:5/11(45.4%)Part A:32/55(58.2)%);PartB:8/11(72.7%)Part A:the median PFS was 5.7 months (95% CI: 3.7, 9.5);PartB:the median PFS was 5.5 months (95% CI: 1.8, 9.1)NALAG525(anti-LAG-3) ± spartalizumab (PDR001,anti-PD-1)NCT02460224advanced malignancies1/2119 (LAG525),121 (LAG525 + spartalizumab)fatigue (18%), diarrhea (15%), and nausea (12%)10 (8%) in the LAG525, 10(8%) in the combination0 in the LAG525, 12/121(10%) in the combinationNANANAeftilagimod alpha(recombinant LAG-3Ig fusion protein) together with pembrolizumab(anti-PD-1)NCT02676869unresectable or metastatic melanoma118NA22.20%8/16(50%)NANANAIBI110 (anti-LAG-3 mAb)NCT05572463Unresectable or Metastatic Cutaneous Melanoma1/20NANANANANANAINCAGN02385(anti-LAG-3)NCT03538028Select Advanced Malignancies122NANANANANANARO7247669(an anti PD-1 and LAG-3 bispecific antibody)NCT04140500Advanced and/or Metastatic Solid Tumors1/2320NANANANANANAINCA32459 (a LAG-3 and PD-1 Bispecific Antibody)NCT05577182Select Advanced Malignancies1120NANANANANANAINCAGN02390(Anti-TIM-3)NCT03652077Advanced Malignancies140100%7.50%1/40(2.5%)7/40(17.5%)NANACombination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3)NCT04370704advanced solid tumors1/221 were enrolled in parts 1 (n = 10)(INCAGN02385 + INCAGN02390) and 2 (n = 11)(INCAGN02385 + INCAGN02390 + retifanlimab)90%(part1),91% (part2)20%(part1),27%(part2)NANANANAcobolimab(TIM-3 inhibitor) monotherapy and in combination ith nivolumab or dostarlimab(PD-1 inhibitors)NCT02817633advanced solid tumors1104 were included: 1A(cobolimab) n = 46, 1B(cobolimab + nivolumab) n = 7, 1C(cobolimab + dostarlimab) n = 5567.4% (1A), 85.7% (1B), and 67.3% (1C)4.3% (1A), 28.6% (1B), and 14.5% (1C)0(1A),42.9%(1B),16.4%(1C)20.7%(1A),42.9%(1B),45.5%%(1C)NANAdostarlimab (anti–PD-1) monotherapy or dostarlimab plus cobolimab (anti–TIM-3)NCT04139902resectable stage III melanoma257(Arm A mono: n = 30; Arm B comb: n = 27)NA16.7% in A, 14.9% in BNANANANASabatolimab(an Anti-TIM-3 Antibody) alone and in Combination with Spartalizumab(an Anti-PD-1 Antibody)NCT02608268advanced solid tumors1/1b219,sabatolimab (n = 133) or sabatolimab plus spartalizumab (n = 86)fatigue (9%, sabatolimab; 15%, combination)00(sabatolimab),5/86 6%(combination)0(sabatolimab),5/86 6%(combination)NANALomvastomig(PD-1/TIM-3 Bispecific Antibody)NCT03708328Advanced and/or Metastatic Solid Tumors1134NANANANANANATQB2618(Anti-TIM-3) Injection Combined With Toripalimab(Anti-PD-1)NCT05451407Advanced Melanoma150NANANANANANALY3475070(anti-CD73 antibody)NCT04148937Advanced Cancer152NANANANANANABMS-986179 (anti CD73) ± Nivolumab (anti PD-1)NCT02754141Malignant Solid Tumor123565.1%, BMS-986179 + Nivo group (85.5%),BMS-986179 (36.1%)3.4%, BMS-986179 + Nivo group (5.8%),BMS-986179 (0%)4.7%, BMS-986179 + Nivo group (7.2%),BMS-986179 (1.0%)NABMS-986179 + Nivo group (78.2%),BMS-986179 (30.9%)NAUliledlimab(TJD5, anti CD73) ± toripalimab (anti PD-1)NCT04322006Advanced Solid Tumor170NA20%31.3%83.6%NANAUliledlimab (TJ004309, antiCD73) in combination with atezolizumab (anti PD-L1)NCT03835949Solid Tumor, Metastatic Cancer120NA0%23%46%NANAOleclumab (anti CD73)alone or incombination withDurvalumab(anti PD-L1)NCT02503774Solid Tumors1192Oleclumab + durvalumab group (54%),Oleclumab (55%)Oleclumab + durvalumab group (21%), Oleclumab (7%)0%4.8%the median PFS in Oleclumab + durvalumab group (1.8 months),the median PFS in the Oleclumab group (1.8 months)the median OS in the Oleclumab + durvalumab group (5.6 months),the median OS in the Oleclumab group (6.1 months)CPI-006 (anti CD73)Alone and inCombination WithCPI-444 (A2A Receptor Antagonist)and With Pembrolizumab (anti PD-1)NCT03454451Solid Tumors117, CPI-006 + CPI-444 (n = 6) or CPI-006 (n = 11)CPI-006 + CPI-444 group (66.7%), CPI-006 (63.6%)CPI-006 + CPI-444 group (0%),CPI-006 (0%)5.9%, CPI-006 + CPI-444 group (0%),CPI-006 (9.1%)17.6%, CPI-006 + CPI-444 group (16.7),CPI-006 (18.2%)82.4%,the median PFS in the CPI-006 group (8 months)35.3%,CPI-006 + CPI-444 group (33.3%),CPI-006 (36.4%)Dalutrafusp Alfa(GS-1423, anti– CD73-­ TGF-β)NCT03954704Advanced Solid Tumors122100%42.9%4.8%38.1%the median PFS (1.8 months [95% CI, 1.7–2.7])the median OS (5.5 months [95% CI, 3.7–10.1])BMS-986179 (anti CD73) ± Nivolumab (anti PD-1)NCT02754141Malignant Solid Tumor123565.1%, BMS-986179 + Nivo group (85.5%),BMS-986179 (36.1%)3.4%, BMS-986179 + Nivo group (5.8%),BMS-986179 (0%)4.7%, BMS-986179 + Nivo group (7.2%),BMS-986179 (1.0%)NABMS-986179 + Nivo group (78.2%),BMS-986179 (30.9%)NAEtigilimab (TIGIT Inhibitor) plus nivolumab (anti PD-1)NCT04761198advanced solid tumors (including uveal melanoma)1b/227 (6 uveal melanoma)25%011% (0 in uveal melanoma)44% (3/6 in uveal melanoma)NANAPembrolizumab(anti PD-1))/Vibostolimab (MK-7684A,TIGIT Inhibitor)Versus PembrolizumabNCT05665595Melanoma31560NANANANANANAZimberelimab (AB122,anti PD-1) With Domvanalimab (AB154,TIGIT Inhibitor)NCT05130177Melanoma226NANANANANANAAB308(TIGIT inhibitor) in combination with zimberelimab (AB122,PD-1 inhibitor)NCT04772989Advanced Malignancies194NANANANANANAAtezolizumab and TiragolumabNCT05483400Solid Tumors297NANANANANANATiragolumab Plus Atezolizumab Versus AtezolizumabNCT05060003Stage II Melanoma2244NANANANANANAVemurafenib, Cobimetinib, Atezolizumab, and TiragolumabNCT03554083High-Risk Stage III Melanoma230NANANANANANAFPT155(a CD28 stimulator)NCT04074759Advanced Solid Tumors180NANANANANANAREGN7075 (EGFRxCD28 costimulatory bispecific antibody)in combination with cemiplimab (anti–PD-1)NCT04626635advanced solid tumors1/218fatigue (17% [n = 3]), increases in AST, diarrhea, hypothyroidism, pyrexia, and rash (11% [n = 2] each)01/18(5.6%)1/18(5.6%)NANAEnoblituzumab (MGA271,CD276 inhibitor) in Combination With Ipilimumab(CTLA-4 inhibitor)NCT02381314Melanoma,Non-Small Cell Lung Cancer124NANANANANANAEnoblituzumab (MGA271,CD276 inhibitor) in Combination With Pembrolizumab(PD-1 inhibitor)NCT02475213advanced solid tumors1/2133(13 melanoma)87.2% (116/133)28.6% (38/133)7.7% (1/13)46.2% (6/13)Median PFS 2.07 mo (1.31 to 9.82)Median OS 14.19 mo (4.76 to NR)MGC018(an anti-B7-H3 antibody–drug conjugate (ADC))NCT03729596advanced solid tumors129100%6.90%NANANANAMGC018(an anti-B7-H3 antibody–drug conjugate (ADC)) in Combination With MGD019(a bispecific DART protein binding PD-1 and CTLA-4)NCT05293496advanced solid tumors1278NANANANANANAMGD009(B7-H3 x CD3 Dual Affinity Re-Targeting (DART) protein)NCT02628535melanoma,NSCLC,SCCHN,mesothelioma and urothelial cancer167NANANANANANAMGD009(a humanized B7-H3 x CD3 DART protein) in combination with MGA012(an anti-PD-1 antibody)NCT03406949relapsed or refractory B7-H3-expressing tumors125NANANANANANATAA06(CD276 inhibitor)NCT05190185Malignant Melanoma, Lung Cancer, or Colorectal Cancer118NANANANANANAB7H3 chimeric antigen receptor T cells (CAR-T)NCT04483778relapsed or refractory solid tumors116fatigue and cytokine release syndrome (CRS) (n = 2)03/9(33.3%)NANANAB7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell TherapyNCT04897321Solid Tumors132NANANANANANA Table 7Clinical trials of other immune checkpoint inhibitorsDrugsNCT numberConditionsPhasesNumber of ParticipantsAEsEfficacyall grade TRAEs >/= G3 TRAEsORRDCRPFSOSnivolumab (anti PD-1) with relatlimab (anti LAG-3)NCT03470922first-line advanced melanoma3714, RELA + NIVO FDC (n = 355) or NIVO (n = 359)NARELA + NIVO FDC group (18.9%), NIVO (9.7%RELA + NIVO FDC group (43%), NIVO (33%)NAthe median PFS in the RELA + NIVO group (10.1 months [95% CI, 6.4–15.7]),the median PFS in the NIVO group (4.6 months [95% CI, 3.4–5.6]the median OS in the RELA + NIVO group NR,the median OS in the NIVO group (34 months [95% CI, 25.2–NR]NCT03743766first-line advanced melanoma222proliferative fibrosis(50%), neovascularization(35%), plasma cells(26.3%25%1/22(4.5%)13/22(59%)NANANCT02519322resectable clinical stage III melanoma230NA017/30(57%)NANAthe 1 -year OS was 95%fianlimab (anti-LAG-3) and cemiplimab (anti-PD-1)NCT03005782advanced melanoma198NA43.90%60/98(61.2%)NAthe median PFS was 15.3 months(95% CI: 9.4–NE)NAfianlimab(anti-LAG-3) With Cemiplimab(anti-PD-1) VS Pembrolizumab(anti-PD-1)NCT05608291Delaying Melanoma31530NANANANANANALBL-007 (an anti-LAG-3 antibody) in combination with toripalimab (an anti-PD-1 antibody) or LBL-007 in combination with toripalimab and axitinibNCT04640545advanced melanoma1Part A LBL-007 plus toripalimab:68;Part B LBL-007 plus toripalimab with axitinib:NAPart A:27.9%; PartB:45.5%Part A:13/55(23.6%);PartB:5/11(45.4%)Part A:32/55(58.2)%);PartB:8/11(72.7%)Part A:the median PFS was 5.7 months (95% CI: 3.7, 9.5);PartB:the median PFS was 5.5 months (95% CI: 1.8, 9.1)NALAG525(anti-LAG-3) ± spartalizumab (PDR001,anti-PD-1)NCT02460224advanced malignancies1/2119 (LAG525),121 (LAG525 + spartalizumab)fatigue (18%), diarrhea (15%), and nausea (12%)10 (8%) in the LAG525, 10(8%) in the combination0 in the LAG525, 12/121(10%) in the combinationNANANAeftilagimod alpha(recombinant LAG-3Ig fusion protein) together with pembrolizumab(anti-PD-1)NCT02676869unresectable or metastatic melanoma118NA22.20%8/16(50%)NANANAIBI110 (anti-LAG-3 mAb)NCT05572463Unresectable or Metastatic Cutaneous Melanoma1/20NANANANANANAINCAGN02385(anti-LAG-3)NCT03538028Select Advanced Malignancies122NANANANANANARO7247669(an anti PD-1 and LAG-3 bispecific antibody)NCT04140500Advanced and/or Metastatic Solid Tumors1/2320NANANANANANAINCA32459 (a LAG-3 and PD-1 Bispecific Antibody)NCT05577182Select Advanced Malignancies1120NANANANANANAINCAGN02390(Anti-TIM-3)NCT03652077Advanced Malignancies140100%7.50%1/40(2.5%)7/40(17.5%)NANACombination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3)NCT04370704advanced solid tumors1/221 were enrolled in parts 1 (n = 10)(INCAGN02385 + INCAGN02390) and 2 (n = 11)(INCAGN02385 + INCAGN02390 + retifanlimab)90%(part1),91% (part2)20%(part1),27%(part2)NANANANAcobolimab(TIM-3 inhibitor) monotherapy and in combination ith nivolumab or dostarlimab(PD-1 inhibitors)NCT02817633advanced solid tumors1104 were included: 1A(cobolimab) n = 46, 1B(cobolimab + nivolumab) n = 7, 1C(cobolimab + dostarlimab) n = 5567.4% (1A), 85.7% (1B), and 67.3% (1C)4.3% (1A), 28.6% (1B), and 14.5% (1C)0(1A),42.9%(1B),16.4%(1C)20.7%(1A),42.9%(1B),45.5%%(1C)NANAdostarlimab (anti–PD-1) monotherapy or dostarlimab plus cobolimab (anti–TIM-3)NCT04139902resectable stage III melanoma257(Arm A mono: n = 30; Arm B comb: n = 27)NA16.7% in A, 14.9% in BNANANANASabatolimab(an Anti-TIM-3 Antibody) alone and in Combination with Spartalizumab(an Anti-PD-1 Antibody)NCT02608268advanced solid tumors1/1b219,sabatolimab (n = 133) or sabatolimab plus spartalizumab (n = 86)fatigue (9%, sabatolimab; 15%, combination)00(sabatolimab),5/86 6%(combination)0(sabatolimab),5/86 6%(combination)NANALomvastomig(PD-1/TIM-3 Bispecific Antibody)NCT03708328Advanced and/or Metastatic Solid Tumors1134NANANANANANATQB2618(Anti-TIM-3) Injection Combined With Toripalimab(Anti-PD-1)NCT05451407Advanced Melanoma150NANANANANANALY3475070(anti-CD73 antibody)NCT04148937Advanced Cancer152NANANANANANABMS-986179 (anti CD73) ± Nivolumab (anti PD-1)NCT02754141Malignant Solid Tumor123565.1%, BMS-986179 + Nivo group (85.5%),BMS-986179 (36.1%)3.4%, BMS-986179 + Nivo group (5.8%),BMS-986179 (0%)4.7%, BMS-986179 + Nivo group (7.2%),BMS-986179 (1.0%)NABMS-986179 + Nivo group (78.2%),BMS-986179 (30.9%)NAUliledlimab(TJD5, anti CD73) ± toripalimab (anti PD-1)NCT04322006Advanced Solid Tumor170NA20%31.3%83.6%NANAUliledlimab (TJ004309, antiCD73) in combination with atezolizumab (anti PD-L1)NCT03835949Solid Tumor, Metastatic Cancer120NA0%23%46%NANAOleclumab (anti CD73)alone or incombination withDurvalumab(anti PD-L1)NCT02503774Solid Tumors1192Oleclumab + durvalumab group (54%),Oleclumab (55%)Oleclumab + durvalumab group (21%), Oleclumab (7%)0%4.8%the median PFS in Oleclumab + durvalumab group (1.8 months),the median PFS in the Oleclumab group (1.8 months)the median OS in the Oleclumab + durvalumab group (5.6 months),the median OS in the Oleclumab group (6.1 months)CPI-006 (anti CD73)Alone and inCombination WithCPI-444 (A2A Receptor Antagonist)and With Pembrolizumab (anti PD-1)NCT03454451Solid Tumors117, CPI-006 + CPI-444 (n = 6) or CPI-006 (n = 11)CPI-006 + CPI-444 group (66.7%), CPI-006 (63.6%)CPI-006 + CPI-444 group (0%),CPI-006 (0%)5.9%, CPI-006 + CPI-444 group (0%),CPI-006 (9.1%)17.6%, CPI-006 + CPI-444 group (16.7),CPI-006 (18.2%)82.4%,the median PFS in the CPI-006 group (8 months)35.3%,CPI-006 + CPI-444 group (33.3%),CPI-006 (36.4%)Dalutrafusp Alfa(GS-1423, anti– CD73-­ TGF-β)NCT03954704Advanced Solid Tumors122100%42.9%4.8%38.1%the median PFS (1.8 months [95% CI, 1.7–2.7])the median OS (5.5 months [95% CI, 3.7–10.1])BMS-986179 (anti CD73) ± Nivolumab (anti PD-1)NCT02754141Malignant Solid Tumor123565.1%, BMS-986179 + Nivo group (85.5%),BMS-986179 (36.1%)3.4%, BMS-986179 + Nivo group (5.8%),BMS-986179 (0%)4.7%, BMS-986179 + Nivo group (7.2%),BMS-986179 (1.0%)NABMS-986179 + Nivo group (78.2%),BMS-986179 (30.9%)NAEtigilimab (TIGIT Inhibitor) plus nivolumab (anti PD-1)NCT04761198advanced solid tumors (including uveal melanoma)1b/227 (6 uveal melanoma)25%011% (0 in uveal melanoma)44% (3/6 in uveal melanoma)NANAPembrolizumab(anti PD-1))/Vibostolimab (MK-7684A,TIGIT Inhibitor)Versus PembrolizumabNCT05665595Melanoma31560NANANANANANAZimberelimab (AB122,anti PD-1) With Domvanalimab (AB154,TIGIT Inhibitor)NCT05130177Melanoma226NANANANANANAAB308(TIGIT inhibitor) in combination with zimberelimab (AB122,PD-1 inhibitor)NCT04772989Advanced Malignancies194NANANANANANAAtezolizumab and TiragolumabNCT05483400Solid Tumors297NANANANANANATiragolumab Plus Atezolizumab Versus AtezolizumabNCT05060003Stage II Melanoma2244NANANANANANAVemurafenib, Cobimetinib, Atezolizumab, and TiragolumabNCT03554083High-Risk Stage III Melanoma230NANANANANANAFPT155(a CD28 stimulator)NCT04074759Advanced Solid Tumors180NANANANANANAREGN7075 (EGFRxCD28 costimulatory bispecific antibody)in combination with cemiplimab (anti–PD-1)NCT04626635advanced solid tumors1/218fatigue (17% [n = 3]), increases in AST, diarrhea, hypothyroidism, pyrexia, and rash (11% [n = 2] each)01/18(5.6%)1/18(5.6%)NANAEnoblituzumab (MGA271,CD276 inhibitor) in Combination With Ipilimumab(CTLA-4 inhibitor)NCT02381314Melanoma,Non-Small Cell Lung Cancer124NANANANANANAEnoblituzumab (MGA271,CD276 inhibitor) in Combination With Pembrolizumab(PD-1 inhibitor)NCT02475213advanced solid tumors1/2133(13 melanoma)87.2% (116/133)28.6% (38/133)7.7% (1/13)46.2% (6/13)Median PFS 2.07 mo (1.31 to 9.82)Median OS 14.19 mo (4.76 to NR)MGC018(an anti-B7-H3 antibody–drug conjugate (ADC))NCT03729596advanced solid tumors129100%6.90%NANANANAMGC018(an anti-B7-H3 antibody–drug conjugate (ADC)) in Combination With MGD019(a bispecific DART protein binding PD-1 and CTLA-4)NCT05293496advanced solid tumors1278NANANANANANAMGD009(B7-H3 x CD3 Dual Affinity Re-Targeting (DART) protein)NCT02628535melanoma,NSCLC,SCCHN,mesothelioma and urothelial cancer167NANANANANANAMGD009(a humanized B7-H3 x CD3 DART protein) in combination with MGA012(an anti-PD-1 antibody)NCT03406949relapsed or refractory B7-H3-expressing tumors125NANANANANANATAA06(CD276 inhibitor)NCT05190185Malignant Melanoma, Lung Cancer, or Colorectal Cancer118NANANANANANAB7H3 chimeric antigen receptor T cells (CAR-T)NCT04483778relapsed or refractory solid tumors116fatigue and cytokine release syndrome (CRS) (n = 2)03/9(33.3%)NANANAB7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell TherapyNCT04897321Solid Tumors132NANANANANANA Clinical trials of other immune checkpoint inhibitors 65.1%, BMS-986179 + Nivo group (85.5%), BMS-986179 (36.1%) 3.4%, BMS-986179 + Nivo group (5.8%), BMS-986179 (0%) 4.7%, BMS-986179 + Nivo group (7.2%), BMS-986179 (1.0%) BMS-986179 + Nivo group (78.2%), BMS-986179 (30.9%) Uliledlimab (TJD5, anti CD73) ± toripalimab (anti PD-1) Oleclumab (anti CD73) alone or in combination with Durvalumab (anti PD-L1) Oleclumab + durvalumab group (54%), Oleclumab (55%) the median PFS in Oleclumab + durvalumab group (1.8 months), the median PFS in the Oleclumab group (1.8 months) the median OS in the Oleclumab + durvalumab group (5.6 months), the median OS in the Oleclumab group (6.1 months) CPI-006 (anti CD73) Alone and in Combination With CPI-444 (A2A Receptor Antagonist) and With Pembrolizumab (anti PD-1) CPI-006 + CPI-444 group (0%), CPI-006 (0%) 5.9%, CPI-006 + CPI-444 group (0%), CPI-006 (9.1%) 17.6%, CPI-006 + CPI-444 group (16.7), CPI-006 (18.2%) 82.4%, the median PFS in the CPI-006 group (8 months) 35.3%, CPI-006 + CPI-444 group (33.3%), CPI-006 (36.4%) Dalutrafusp Alfa (GS-1423, anti– CD73-­ TGF-β) 65.1%, BMS-986179 + Nivo group (85.5%), BMS-986179 (36.1%) 3.4%, BMS-986179 + Nivo group (5.8%), BMS-986179 (0%) 4.7%, BMS-986179 + Nivo group (7.2%), BMS-986179 (1.0%) BMS-986179 + Nivo group (78.2%), BMS-986179 (30.9%) 133 (13 melanoma) Clinical picture of TIM-3 inhibitor drugs TIM-3 antibodies are being studied in multiple clinical trials, showing preliminary initial outcomes. INCAGN02390, a fully human Fc-engineered IgG1κanti-TIM-3 monoclonal antibody, has finished a Phase I trial (NCT03652077) involving patients with melanoma and other advanced malignancies (n = 40). All participants experienced TRAEs, with 7.5% reporting grade 3 or higher TRAEs. One patient achieved PR, and six patients had SD, yielding an ORR of 64.6% and a DCR of 17.5% [249, 250]. A Phase I/II study (NCT04370704) is ongoing to assess various combinations of INCAGN02390 with INCMGA00012 (Anti-PD-1) and INCAGN02385 (Anti-LAG-3) in patients with advanced cancers, including melanoma [251]. Neoadjuvant dual PD-1/TIM-3 blockade represents a strategy to enhance pathological responses in resectable melanoma. Cobolimab (TSR-022), an anti-TIM-3 mAb, is being evaluated in a Phase I study (NCT02817633) as a standalone treatment or combined with nivolumab (anti-PD-1) or dostarlimab (anti-PD-1) for patients with melanoma or other advanced solid tumors. The study enrolled 104 patients, randomized into three groups: 1 A (cobolimab, n = 46), 1B (cobolimab + nivolumab, n = 7), and 1 C (cobolimab + dostarlimab, n = 55). The most common malignancies included NSCLC and melanoma (1A), NSCLC (1B), and NSCLC, skin cancer, and peritoneal mesothelioma (1C). Grade 3 or higher TRAEs were observed in 4.3% of 1 A, 28.6% of 1B, and 14.5% of 1 C participants. The ORR was 0% in 1 A, 42.9% in 1B, and 16.4% in 1 C, with DCRs of 20.7%, 42.9%, and 45.5%, respectively [252]. The phase II NEO-MEL-T trial randomized 57 patients to neoadjuvant dostarlimab monotherapy or dostarlimab plus cobolimab prior to surgery. The combination achieved a major pathological response rate of 51.9% versus 33.3% with monotherapy and significantly exceeded historical neoadjuvant anti–PD-1 benchmarks. With comparable grade ≥ 3 immune-related adverse events between arms (14.9% versus 16.7%), The combination yielded a favorable 1-year event-free survival estimate of 92% and supports continued clinical evaluation of PD-1/TIM-3 dual blockade as an investigational strategy in melanoma [253]. Sabatolimab (MBG453), another anti-TIM-3 agent, demonstrated favorable tolerance but limited efficacy in a Phase II study (NCT02608268), where 219 participants were treated with sabatolimab in combination with spartalizumab (Anti-PD-1) [254]. Lomvastomig, a PD-1/TIM-3 bispecific antibody, is under investigation in a Phase I trial (NCT03708328) involving 134 patients with various cancers, including melanoma [255]. TQB2618, a humanized IgG4 anti-TIM-3 mAb, is being evaluated in a Phase I trial (NCT05451407) in combination with Toripalimab (anti-PD-1) for patients with advanced melanoma (n = 50) [256] (Table 7). Although TIM-3 blockade represents a biologically rational strategy to counteract T-cell exhaustion and overcome resistance to PD-1 inhibition, clinical evidence in melanoma remains preliminary and confined to early-phase trials. Comparative efficacy data underscore the limited clinical advancement of TIM-3 blockade in melanoma relative to established standards. To date, no TIM-3-directed agent has demonstrated efficacy sufficient to support regulatory approval or routine clinical use in melanoma, and its therapeutic value relative to established PD-1 or LAG-3 based regimens remains to be defined in larger randomized studies. Clinical picture of CD73 inhibitor drugs CD73 has emerged as a new immune checkpoint target, with multiple early-phase clinical trials currently investigating CD73-targeting agents either as monotherapies or in combination with other immunotherapeutic strategies. These studies primarily focus on patients with advanced or metastatic solid tumors, aiming to evaluate the safety, tolerability, and preliminary efficacy of CD73 blockade. BMS-986179, a humanized anti-CD73 monoclonal antibody, is being evaluated in a Phase I trial (NCT02754141) involving 235 patients with malignant solid tumors. The study compares BMS-986179 as monotherapy versus in combination with nivolumab (anti-PD-1) [257]. Uliledlimab (TJD5), another anti-CD73 antibody, is under investigation in two separate Phase I trials (NCT04322006, NCT03835949) [258]. In NCT04322006, uliledlimab is tested alone or in combination with toripalimab (anti-PD-1) in 70 patients with advanced solid tumors [259]. Oleclumab, a first-in-class anti-CD73 antibody, has been evaluated in a Phase I trial (NCT02503774) involving 192 patients with solid tumors. The study assessed both monotherapy and combination with durvalumab (anti-PD-L1) [260]. CPI-006, a humanized anti-CD73 antibody, is being tested in a small Phase I trial (NCT03454451) involving 17 patients with solid tumors. The study includes both monotherapy and combination arms with either CPI-444 (an A2A receptor antagonist) or pembrolizumab (anti-PD-1) [261]. Dalutrafusp alfa (GS-1423), a bifunctional fusion protein targeting both CD73 and TGF-β, is under evaluation in a Phase I trial (NCT03954704) involving 22 patients with advanced solid tumors [262]. Additionally, LY3475070, another anti-CD73 antibody, is being investigated in a Phase I monotherapy trial (NCT04148937) involving 52 patients with advanced tumors; however, no clinical data have been disclosed to date. Collectively, these early-phase trials underscore the potential of CD73 blockade as a component of combination immunotherapy, particularly with PD-1/PD-L1 inhibitors. Ongoing and future studies are anticipated to clarify the therapeutic value of CD73 inhibition in the evolving landscape of cancer immunotherapy (Table 7). The clinical positioning of CD73 blockade in melanoma remains distinctly investigational when benchmarked against approved therapeutic standards. Unlike pembrolizumab, nivolumab, CD73-targeted agents have not advanced to melanoma-specific phase II or III studies, and available phase I data across unselected solid tumors reveal limited antitumor activity. For instance, oleclumab combined with durvalumab achieved an objective response rate of 0% and a median progression-free survival of only 1.8 months, while BMS-986179 plus nivolumab yielded a 7.2% objective response rate, figures that fall substantially below the efficacy thresholds established by standard-of-care checkpoint inhibitors. CD73 inhibition currently lacks evidence to support its clinical utility in melanoma and should be regarded strictly as an experimental strategy awaiting definitive validation. Clinical picture of CD155-TIGIT inhibitor drugs TIGIT is a prominent target in numerous ongoing clinical trials exploring combinatorial regimens. Etigilimab, a humanized IgG1 monoclonal antibody targeting TIGIT, disrupts its interaction with PVR and inhibits downstream immunosuppressive signaling. In the phase 1b/2 ACTIVATE basket trial (NCT04761198), etigilimab plus nivolumab was evaluated across six cohorts of advanced solid tumors, including a rare cancer arm encompassing uveal melanoma. Among 6 efficacy-evaluable uveal melanoma patients, the combination demonstrated a disease control rate of 50%, with durable stable disease exceeding 20 weeks. The regimen was well tolerated without new safety signals, supporting continued investigation of TIGIT-directed combination strategies in immunotherapy-refractory malignancies [263]. Vibostolimab (MK-7684A), a TIGIT inhibitor, is being investigated in a phase-III trial (NCT05665595) comparing pembrolizumab (PD-1 antibody) plus vibostolimab versus pembrolizumab alone in patients with melanoma (n = 1560) [264]. This trial was terminated early after interim analysis revealed no progression-free survival benefit versus pembrolizumab monotherapy, mirroring the failure of tiragolumab to improve outcomes in phase III lung cancer studies and underscoring the challenges of translating TIGIT blockade into clinical advantage. Another TIGIT inhibitor, domvanalimab (AB154), is being evaluated in a phase-II single-arm study for PD-1 refractory melanoma patients, assessing its combination with zimberelimab (AB122, PD-1 antibody) (NCT05130177) [265]. Additionally, a phase-I trial is examining the combination of the anti-TIGIT antibody AB308 with the anti-PD-1 zimberelimab in participants with advanced malignancies (NCT04772989). Tiragolumab (RG6058), another TIGIT inhibitor, is being tested in phase-II clinical trials for melanoma in combination with the PD-L1 antibody atezolizumab (NCT05483400, NCT05060003, NCT03554083) [266] (Table 7). By late 2024, Roche had terminated the majority of its tiragolumab clinical program, and across the industry, 8 of 30 TIGIT inhibitors (27%) had been discontinued due to failure to demonstrate significant clinical activity, with none having received regulatory approval as of November 2025 [267]. Given the absence of completed positive phase III trials in melanoma or any other malignancy, the consistent pattern of negative or marginal efficacy data, and the lack of regulatory approvals, TIGIT-directed therapy in melanoma should be regarded as an unvalidated experimental approach with no current role in standard clinical practice. Clinical picture of CD28 inhibitor drugs CD28 stimulators have garnered significant interest in both preclinical studies and clinical trials. FPT155, a CD28 stimulator, is currently advancing to phase I clinical trials (NCT04074759) [268]. Additionally, REGN7075, a bispecific antibody targeting EGFR/CD28 costimulation, has completed a phase I/II trial in combination with cemiplimab (anti-PD-1 antibody) for patients with advanced solid tumors (NCT04626635). Notably, no participants experienced grade 3 or higher TRAEs. In this trial, one patient out of 18 who received 1 mg of REGN7075 with cemiplimab for cervical cancer achieved an ongoing PR, yielding an ORR of 5.6% (Table 7) [269]. The clinical development of CD28-targeted agents in melanoma remains in its earliest infancy, with no agent having demonstrated melanoma-specific efficacy or advanced beyond phase I investigation. Clinical picture of CD276 inhibitor drugs Based on the preclinical research data and ongoing clinical trials, several therapeutic approaches targeting CD276 as an immune checkpoint have been explored with varying results. Enoblituzumab (MGA271), an anti-CD276 monoclonal antibody, was tested in combination with ipilimumab (anti-CTLA-4) in a phase I study involving patients with melanoma or non-small cell lung cancer (NSCLC) (NCT02381314) [170]. Although the safety and toxicity profiles were reported, clinical outcomes have not yet been disclosed. Vobramitamab duocarmazine (MGC018), an anti-CD276 antibody–drug conjugate (ADC), is undergoing evaluation in a phase I clinical trial as a monotherapy for advanced solid tumors (NCT03729596). The safety data show that 6.9% of patients experienced grade 3 or higher TRAEs, though efficacy data have not yet been released [270]. The phase I/II trial NCT02475213 evaluated enoblituzumab, a B7-H3-targeting monoclonal antibody, in combination with pembrolizumab in patients with B7-H3-expressing solid tumors, including a melanoma cohort. While the combination demonstrated manageable safety, antitumor activity in melanoma was modest with an objective response rate of 7.7%, contrasting with more efficacy observed in checkpoint inhibitor-naïve head and neck squamous cell carcinoma and non-small cell lung cancer [271]. A separate phase I trial is investigating the combination of Vobramitamab duocarmazine with MGD019, a bispecific dual-affinity re-targeting (DART) protein targeting PD-1 and CTLA-4, but results are still pending (NCT05293496). MGD009, a humanized B7-H3 x CD3 DART protein, is also being investigated in two clinical trials (NCT02628535, NCT03406949) [272, 273]. Research into CAR T-cell immunotherapy focusing on B7-H3 for melanoma is ongoing in various clinical trials (NCT05190185, NCT04483778, NCT04897321) [274, 275]. In one trial (NCT04483778), 33.3% of patients (3/9) achieved ORR, demonstrating potential clinical efficacy for this approach [276]. It is an early-phase finding derived from a heavily pretreated, small cohort with no durability or survival data. The IDeate-PanTumor02 trial (NCT06330064) is an ongoing phase Ib/II basket study evaluating ifinatamab deruxtecan, a B7-H3-directed antibody–drug conjugate, in patients with recurrent or metastatic solid tumors, including a cohort of cutaneous melanoma [277]. The phase II trial NCT06953089 is evaluating the combination of DB-1311, a B7-H3-directed antibody–drug conjugate, with BNT327, a PD-L1 × VEGF-A bispecific antibody, in patients with advanced solid tumors including melanoma [278] (Table 7). Overall, no CD276-targeted agent has completed phase II evaluation specifically in melanoma, and none have received regulatory approval in any indication. Other immune checkpoint targets In addition to CD276, CD74 (also known as the MHC class II invariant chain) is another immune checkpoint that regulates immune cell development and inflammatory processes. CD74 activation, through its receptor complex with CD44, triggers several intracellular signaling pathways, including ERK1/2, PI3K-Akt, NF-κB, and adenosine monophosphate-activated protein kinase (AMPK) pathways [279]. A phase I study of TTI-621, a CD74-targeting drug, in patients with relapsed or refractory mycosis fungoides, Sézary syndrome, or solid tumors showed preliminary results. Among the 29 evaluable patients, 26 (90%) experienced a decrease in Composite Assessment of Index Lesion Severity (CAILS) scores (NCT02890368) [280]. CD137 (4-1BB), a key costimulatory receptor in the tumor necrosis factor receptor superfamily (TNFRSF), is another target for immunotherapy. CD137 is upregulated upon activation of T-cells, B-cells, and NK cells, and its activation promotes enhanced cell proliferation and survival [281]. The clinical advancement of urelumab, the initial human anti-CD137 IgG4 agonist antibody, was stopped because of dose-related liver toxicity, which included grade 3 and more severe liver toxicity and resulted in two fatalities despite evidence of efficacy in melanoma patients [282]. This highlights the potential but also the risks of targeting CD137 in immunotherapy. Nevertheless, ongoing clinical studies are exploring how to modulate this pathway for therapeutic benefit, and CD137-targeted immunotherapy remains a new area for future research. Conclusion and discussion Immune checkpoint blockade has transformed the treatment landscape of advanced melanoma, but its clinical benefit remains uneven across patients. At present, the most firmly established regimens are pembrolizumab, nivolumab-based therapy, nivolumab plus ipilimumab, and nivolumab plus relatlimab (Table 8). These regimens have produced the most mature gains in response and survival, yet they are also limited by primary resistance, acquired resistance after initial benefit, and clinically significant immune-related adverse events. In particular, dual checkpoint blockade can improve efficacy at the cost of substantially increased toxicity, highlighting the persistent trade-off between treatment intensity and tolerability.Table 8Comparative overview of landmark phase III or key registrational trials of immune checkpoint-based therapy in advanced melanomaDrugsNCT numberConditions >/= G3 TRAEsEfficacyClinical interpretationORRMedian PFSMedian OSIpilimumab plus dacarbazine vs dacarbazineNCT00324155untreated metastatic melanoma56.3% vs 27.5%15.2% vs 10.3%19.3 vs 8.1 months11.2 vs. 9.1 monthsEstablished that CTLA-4 blockade provides durable benefit over chemotherapy and supports Ipilimumab as a standard first-line optionPembrolizumab VS IpilimumabNCT01866319ipilimumab-refractory Melanoma13.3% VS 19.9%42% vs 17%5.5 vs 2.8 month32.7 VS 15.9 monthsEstablished that PD-1 blockade provides durable benefit over chemotherapy and supports Pembrolizumab as a standard first-line optionNivolumab vs dacarbazineNCT01721772Previously untreated advanced melanoma, BRAF wild-type60.68% vs 58.05%42% vs 14%5.06 vs not emphasized in comparator summary39% vs 17% overall survival rate at 5 yearsEstablished that PD-1 blockade provides durable benefit over chemotherapy and supports nivolumab as a standard first-line optiontoripalimab vs dacarbazineNCT03430297advanced melanoma15%14% vs 11%(DOR) 13.8 vs 6.9 monthsNASupports toripalimab as a standard first-line option approved by NMPANivolumab + ipilimumab vs nivolumabvs ipilimumabNCT01844505Unresectable or metastatic melanoma79.55% vs 59.74% vs 65.92%58.3% vs 44.9% vs 19.0%11.5 vs 6.87 vs 2.89 months71.9 vs 36.9 vs 19.9 monthsDemonstrates the strongest long-term survival benefit among established regimens, but at the cost of substantially increased toxicityNivolumab + relatlimab vs nivolumabNCT03470922Untreated unresectable or metastatic melanoma18.9% vs 9.7%43% vs 33%10.1 vs 4.6 monthsNASupports PD-1/LAG-3 blockade as an approved option with improved PFS and a more tolerable profile than CTLA-4/PD-1 dual blockadeLenvatinib + pembrolizumab vs pembrolizumab aloneLEAP-003/China extension (global NCT03820986; China extension NCT04889118)First-line unresectable or metastatic melanoma62.5% vs 16.4% in China extension26.6% vs 16.4% in China extension6.1 vs 2.0 months in China extension19.9 vs 17.0 months in China extension; no OS benefit in the global phase III studyRemains investigational; subgroup activity, particularly in mucosal melanoma, should not be interpreted as establishing a new standard because the global phase III study did not demonstrate OS benefitBRAF/MEK inhibition vs combination nivolumab/ipilimumabNCT02224781treatment-naive BRAFV600-mutant metastatic melanoma59.5% in arm A, 53.1% in arm B, 53.8% in arm C, and 50.0% in arm Darm A: 46.0%; arm B: 43.0%; arm C: 47.8%; and arm D: 29.6%NAThe 2-year OS for those starting on arm A was 71.8% (95% CI, 62.5 to 79.1) and arm B 51.5% (95% CI, 41.7 to 60.4; log-rank P =.010)supports immune therapy as the preferred first-line approach in this population, with targeted therapy reserved for post-progression salvage Table 8Comparative overview of landmark phase III or key registrational trials of immune checkpoint-based therapy in advanced melanomaDrugsNCT numberConditions >/= G3 TRAEsEfficacyClinical interpretationORRMedian PFSMedian OSIpilimumab plus dacarbazine vs dacarbazineNCT00324155untreated metastatic melanoma56.3% vs 27.5%15.2% vs 10.3%19.3 vs 8.1 months11.2 vs. 9.1 monthsEstablished that CTLA-4 blockade provides durable benefit over chemotherapy and supports Ipilimumab as a standard first-line optionPembrolizumab VS IpilimumabNCT01866319ipilimumab-refractory Melanoma13.3% VS 19.9%42% vs 17%5.5 vs 2.8 month32.7 VS 15.9 monthsEstablished that PD-1 blockade provides durable benefit over chemotherapy and supports Pembrolizumab as a standard first-line optionNivolumab vs dacarbazineNCT01721772Previously untreated advanced melanoma, BRAF wild-type60.68% vs 58.05%42% vs 14%5.06 vs not emphasized in comparator summary39% vs 17% overall survival rate at 5 yearsEstablished that PD-1 blockade provides durable benefit over chemotherapy and supports nivolumab as a standard first-line optiontoripalimab vs dacarbazineNCT03430297advanced melanoma15%14% vs 11%(DOR) 13.8 vs 6.9 monthsNASupports toripalimab as a standard first-line option approved by NMPANivolumab + ipilimumab vs nivolumabvs ipilimumabNCT01844505Unresectable or metastatic melanoma79.55% vs 59.74% vs 65.92%58.3% vs 44.9% vs 19.0%11.5 vs 6.87 vs 2.89 months71.9 vs 36.9 vs 19.9 monthsDemonstrates the strongest long-term survival benefit among established regimens, but at the cost of substantially increased toxicityNivolumab + relatlimab vs nivolumabNCT03470922Untreated unresectable or metastatic melanoma18.9% vs 9.7%43% vs 33%10.1 vs 4.6 monthsNASupports PD-1/LAG-3 blockade as an approved option with improved PFS and a more tolerable profile than CTLA-4/PD-1 dual blockadeLenvatinib + pembrolizumab vs pembrolizumab aloneLEAP-003/China extension (global NCT03820986; China extension NCT04889118)First-line unresectable or metastatic melanoma62.5% vs 16.4% in China extension26.6% vs 16.4% in China extension6.1 vs 2.0 months in China extension19.9 vs 17.0 months in China extension; no OS benefit in the global phase III studyRemains investigational; subgroup activity, particularly in mucosal melanoma, should not be interpreted as establishing a new standard because the global phase III study did not demonstrate OS benefitBRAF/MEK inhibition vs combination nivolumab/ipilimumabNCT02224781treatment-naive BRAFV600-mutant metastatic melanoma59.5% in arm A, 53.1% in arm B, 53.8% in arm C, and 50.0% in arm Darm A: 46.0%; arm B: 43.0%; arm C: 47.8%; and arm D: 29.6%NAThe 2-year OS for those starting on arm A was 71.8% (95% CI, 62.5 to 79.1) and arm B 51.5% (95% CI, 41.7 to 60.4; log-rank P =.010)supports immune therapy as the preferred first-line approach in this population, with targeted therapy reserved for post-progression salvage Comparative overview of landmark phase III or key registrational trials of immune checkpoint-based therapy in advanced melanoma Nivolumab + ipilimumab vs nivolumab vs ipilimumab A major challenge in melanoma immunotherapy is the marked heterogeneity of treatment response. Differences in tumor biology, immune microenvironment, disease subtype, prior therapy, and host-related factors all contribute to variable sensitivity to checkpoint inhibition. Consequently, many of the combination strategies summarized in this review, including anti-angiogenic regimens, intralesional therapies, cytokine modulation, microbiome-directed approaches, radiotherapy combinations, and other targeted agents, should be interpreted primarily as efforts to broaden benefit or overcome resistance, rather than as established standards of care. For most of these approaches, the available evidence remains early-phase, non-randomized, or based on selected patient subsets, and mature overall survival data are often lacking. Table 8 summarizes the hierarchy of clinical evidence for major investigational strategies in advanced melanoma. Firstly, anti-angiogenic combinations, exemplified by the phase III LEAP-003 trial of lenvatinib plus pembrolizumab, failed to demonstrate overall survival benefit over pembrolizumab monotherapy in the global population. Although a China-extension subgroup showed improved progression-free survival in mucosal melanoma, this enhanced efficacy was accompanied by a considerable increase in grade 3–5 treatment-related adverse events. Similarly, the phase III KEYVIBE-010 trial evaluating pembrolizumab plus vibostolimab (anti-TIGIT) versus pembrolizumab alone in high-risk resectable melanoma was terminated early after interim analysis revealed no progression-free survival benefit. These negative or marginal phase III results underscore that adding targeted agents to PD-1 blockade does not invariably improve outcomes and may substantially increase toxicity. Second, neoadjuvant strategies represent an area of active phase II investigation with potential for practice-changing impact. The NEO-MEL-T trial demonstrated that neoadjuvant PD-1/TIM-3 blockade achieved a major pathological response rate of 51.9%, exceeding historical benchmarks for PD-1 monotherapy. The Morpheus-Melanoma trial showed that neoadjuvant tobemstomig, a PD-1/LAG-3 bispecific antibody, produced a favorable safety profile compared with nivolumab plus ipilimumab, with grade 3 or higher treatment-related adverse events in only 2.5% versus 22.7% of patients. These neoadjuvant data suggest potential in the context of pathological response as a surrogate endpoint, but their translation into long-term event-free and overall survival awaits phase III validation. Third, adoptive cell therapy has entered clinical practice for melanoma through the accelerated FDA approval of Lifileucel in 2024 for post-PD-1 disease, based on a phase II objective response rate of 31.4%. This approval marks melanoma as the first solid tumor in which tumor-infiltrating lymphocyte therapy has achieved regulatory authorization. However, Lifileucel's positioning is complementary rather than competitive with front-line checkpoint inhibition, as it is indicated specifically after progression on PD-1–based therapy. The core challenge in clinical practice remains primary and acquired resistance to immune checkpoint inhibitors, with mechanisms including impaired antigen presentation, upregulation of alternative immune checkpoints, and an immunosuppressive tumor microenvironment. Although preclinical studies have identified potential therapeutic targets, clinical translation remains inconsistent. Biomarker development and standardized irAE management are unmet clinical needs. To date, no single biomarker can reliably predict treatment response or guide therapeutic selection. Dual checkpoint blockade leads to grade 3–4 irAEs in approximately 55–60% of patients, requiring close clinical monitoring. Future advances will likely rely on precision patient stratification—matching subgroups with specific resistance mechanisms to targeted interventions—rather than empirical combination therapies. Neoadjuvant trials and emerging technologies (e.g., circulating tumor DNA detection and spatial transcriptomics) may facilitate this precision medicine approach, but their clinical utility remains investigational. In summary, melanoma immunotherapy rests on four validated regimens with mature survival data. Most combination strategies discussed in this review remain experimental. Treatment decisions should prioritize these established options, with enrollment in clinical trials serving as the appropriate pathway for accessing investigational therapies. Supplementary Information Supplementary Material 1. Supplementary Material 1.